US Pat. No. 10,797,309

NEGATIVE ELECTRODE ACTIVE MATERIAL AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME

LG CHEM, LTD., Seoul (KR...

1. A negative electrode active material comprising a mixture of a first negative electrode active material and a second negative electrode active material,wherein the first negative electrode active material has a hardness of 1 to 10 kg/mm2 based on Vickers hardness, and
the second negative electrode active material has a higher hardness than that of the first negative electrode active material,
wherein the second negative electrode active material is one or more selected from the group consisting of a metal carbide coated with a metal oxide, an alloy coated with a metal oxide, and a metal coated with a metal oxide, and
wherein the first negative electrode active material is one or more selected from the group consisting of soft carbon, hard carbon, natural graphite, kish graphite, pyrolytic carbon, mesophase pitch-based carbon fiber, meso-carbon microbeads, mesophase pitches, petroleum or coal tar pitch-derived cokes, Al, Zn, Sb, Si, Ge and Sn.
US Pat. No. 10,793,467

CRYSTALLIZED GLASS SEALING MATERIAL

NIHON YAMAMURA GLASS CO.,...


wherein the composition turns, when fired at a temperature of 900-1150° C., into a crystallized glass having a thermal expansion coefficient of 80-110×10?7/° C. at a temperature in the range of 50-850° C.
US Pat. No. 10,793,724

FORMULATION AND METHODS FOR COATING METAL SURFACES

Winimac Coil Spring, Inc....

1. A liquid composition for coating a substrate comprising:a phenoxy resin;
a melamine;
an initiator;
a catalyst;
a nonionic surfactant;
a polyester resin; and
a polybutadiene polyepoxide.
US Pat. No. 10,792,956

LIGHT-WEIGHT INNER TUBE AND RELATED METHODS

Bridgestone Americas Tire...

1. A light-weight inner tube suitable for use inside a pneumatic tire, the inner tube consisting of:a film layer with a wall thickness of 100 to 250 microns and an optional adhesive layer having a thickness of 10-50 microns; and including a stem operably sealed to the inner tube to allow for air inflation of the inner tube; wherein the film layer is comprised of a film material comprising at least one thermoplastic engineering resin and no saturated elastomer, and the film material of the film layer has an oxygen permeability of 8-15 cm3 O2/m2 per day at 25° C., and wherein the film layer is the outer-most layer of the light-weight inner tube and the light-weight inner tube forms a continuous tube, and wherein the inflated outer diameter of the inner tube is about 38 to 46 inches (0.97 to 1.2 meters).
US Pat. No. 10,793,725

SOL-GEL COATING COMPOSITIONS INCLUDING CORROSION INHIBITOR-ENCAPSULATED LAYERED DOUBLE HYDROXIDE AND RELATED PROCESSES

THE BOEING COMPANY, Chic...

1. A CIM-containing sol-gel composition comprising:a corrosion inhibiting material (CIM); and
a polymer composite of one or more alkoxysilanes, a zirconium alkoxide, and an organic acid,wherein the CIM comprises a Zn—Al layered double hydroxide (LDH) composition encapsulating a corrosion inhibiting compound.
US Pat. No. 10,795,263

COMPOSITIONS FOR REMOVING PHOTORESIST

SAMSUNG ELECTRONICS CO., ...

1. A composition for removing photoresist, the composition comprising:an alkyl ammonium fluoride salt in an amount ranging from about 0.5 weight percent to about 10 weight percent, based on a total weight of the composition;
an organic sulfonic acid in an amount ranging from about 1 weight percent to about 20 weight percent, based on the total weight of the composition; and
a lactone-based solvent in an amount ranging from about 70 weight percent to about 98.5 weight percent, based on the total weight of the composition,
wherein:
the alkyl ammonium fluoride salt is represented by the following Chemical Formula:
FN((CH2)nCH3)4  [Chemical Formula]
in the Chemical Formula, n is an integer between 2 and 10,
the organic sulfonic acid includes one or more of methane sulfonic acid, ethane sulfonic acid, I-propane sulfonic acid, para-toluene sulfonic acid, or benzene sulfonic acid, and
the composition is devoid of water.
US Pat. No. 10,793,726

COATING FOR APPLICATORS IN ELECTROSURGERY

AESCULAP AG, Tuttlingen ...

1. A method of preparing an applicator for use in electrosurgery, comprising applying at least one coating of at least one electrically insulating polymer to the applicator, resulting in a polymer coating, wherein the applicator is selected from the group consisting of a clamp, a pair of tweezers and a pair of scissors, further wherein the coating is produced partially or entirely by electrophoretic deposition from a suspension of the polymer in at least one organic solvent, wherein the polymer coating has an electrical breakdown resistance of at least 500 V/mm.
US Pat. No. 10,796,800

METHOD AND SYSTEM FOR MICROBIOME-DERIVED DIAGNOSTICS AND THERAPEUTICS FOR MENTAL HEALTH ASSOCIATED CONDITIONS

PSOMAGEN, INC., Rockvill...

1. A method for characterizing a colorectal cancer condition, the method comprising:receiving an aggregate set of samples from a population of subjects;
for each sample of the aggregate set of samples: determining a microorganism nucleic acid sequence upon fragmenting nucleic acid material of the sample and amplifying the fragmented nucleic acid material with a primer;
generating a microbiome feature dataset for the population of subjects based upon the microorganism nucleic acid sequences;
generating a characterization model of the colorectal cancer condition from the microbiome feature dataset;
based upon the characterization model, generating a therapy model that determines a therapy for correcting the colorectal cancer condition; and
providing the therapy to a subject diagnosed with the colorectal cancer condition based upon the characterization model and the therapy model.
US Pat. No. 10,797,312

SILICON-BASED ANODE ACTIVE MATERIAL AND METHOD FOR MANUFACTURING SAME

Nexeon Ltd., Oxfordshire...

1. A silicon-based anode active material comprising a plurality of particles, wherein for each of the plurality of particles:the particle comprises silicon and oxygen combined with the silicon and a carbon-based conductive layer coated on the outermost surface of the particle, wherein the particle comprises a silicon core, a silicon oxide shell on the silicon core, and the carbon-based conductive layer on the silicon oxide shell; and
boron is doped in the particle,
wherein the content of boron with respect to the total weight of the particle and the doped boron is within the range from 0.01 weight% to 20 weight%,
wherein the content of oxygen in the particle is within the range from 16 weight% to 29 weight%,
wherein the thickness of the silicon oxide shell is within the range from 3 nm to 15 nm and wherein at least a portion of the shell comprises boronated silicon oxide, and
wherein the plurality of particles comprising the silicon core and the silicon oxide shell on the silicon core has an average particle diameter within the range from 10 nm to 300 nm.
US Pat. No. 10,792,702

PASSIVATION COMPOSITION COMPRISING A SILANE-MODIFIED SILICATE COMPOUND

1. A method for using a silane-modified silicate comprising the steps ofat least partially hydrolyzing and/or condensing at least one silane in the presence of at least one silicate at a pH equal to or greater than 8, and then
adjusting to a pH equal to or less than 7 by adding an acid.
US Pat. No. 10,793,727

MATTE PAINT COMPOSITION

Eastman Kodak Company, R...

1. A low-specular-reflectance coating composition, comprising:a binder;
a solvent; and
a plurality of substantially spherical particles having a multimodal particle size distribution;
wherein the multimodal particle size distribution has a distribution function having two or more modes, each mode having a peak defining an associated mode particle size, wherein the distribution function including a first mode having a first peak corresponding to a first particle size, and a second mode having a second peak corresponding to a second particle size;
wherein a mode width parameter for each of the modes is less than or equal to 1.0, the mode width parameter for each mode being given by a ratio of a full-width half-maximum width of that mode to the particle size of that mode;
wherein a ratio of the second particle size to the first particle size is between 1.7-4.0; and
wherein a smallest of the mode particle sizes is greater than or equal to 1.0 microns, and a largest of the mode particle sizes is greater than or equal to 3.0 microns.
US Pat. No. 10,793,471

COMPOSITION BASED ON CALCIUM OXIDE

SIKA TECHNOLOGY AG, Baar...

1. A composition comprising:a) calcium oxide in particle form,
b) an inhibitor for the reaction of calcium oxide with water and
c) water; wherein
the composition is present as a slurry or suspension and contains based on the total weight of the composition:
25-75% by weight of the calcium oxide;
0.5-10% by weight of the inhibitor, the inhibitor being a phosphoric acid ester of a polyhydric alcohol; and
25-75% by weight of the water.
US Pat. No. 10,793,728

SUPERHYDROPHOBIC COATING AND PROCESS OF MAKING SAME

1. A process of forming a hydrophobic coating, the process comprising:placing diatomaceous earth into a vessel;
introducing carbon dioxide into the vessel to at least partially infiltrate interstitial voids of the diatomaceous earth;
adding a binder material to the vessel; and
mixing the diatomaceous earth, the carbon dioxide, and the binder material to form a hydrophobic coating.
US Pat. No. 10,793,472

ANTI-SAGGING GYPSUM PRODUCT AND A METHOD TO MANUFACTURE

SAINT-GOBAIN PLACO, (FR)...

1. A gypsum board composition, comprising:gypsum, starch, and an anti-deformation additive,
wherein the anti-deformation additive is selected from L-Ascorbyl 6-palmitate, L-Ascorbyl stearate, Benzene-1,2,3-triol, or any combination thereof, and
wherein a mass percentage of the anti-deformation additive ranges from 0.1% to 5% of the mass of the gypsum.
US Pat. No. 10,793,729

ORGANOCLAY COMPOSITIONS HAVING QUATERNARY AMMONIUM ION HAVING ONE OR MORE BRANCHED ALKYL SUBSTITUENTS

ELEMENTS SPECIALTIES, INC...

1. A coating composition comprising:a non-aqueous solvent;
an organoclay composition comprising:
a synthetic phyllosilicate clay; and
a mixture of quaternary ammonium ions, each ion having a formula of [N—R1R2R3R4]+ wherein, within such mixture of quaternary ammonium ions, one or more of R1, R2 and R3 is a mixture of branched alkyl groups, each branched alkyl group having 12 to 22 total carbon atoms, a linear backbone and one or more C1 to C3 branching alkyl groups each attached to the linear backbone at a branching carbon position, and within each quaternary ammonium ion and within the mixture of branched alkyl groups, the C1 to C3 branching alkyl groups are linked to the linear backbones at different branching carbon positions as a distribution; and wherein when one or more of R2 and R3 is not a branched alkyl group, R2 and R3 are a first linear alkyl group having 1 to 22 carbon atoms, wherein R4 is selected from the group consisting of a second linear alkyl group having 1 to 6 carbon atoms, an aryl group, and combinations thereof.
US Pat. No. 10,793,473

CROSSLINKED POLYSACCHARIDE COMPOSITIONS AND CONCRETE BLENDS CONTAINING THE SAME

HPPE, LLC, Columbus, GA ...

1. A composition comprising:a biologically sourced surfactant; and
a crosslinked polysaccharide, the crosslinked polysaccharide comprising at least one crosslinking group that is bonded via a first ether linkage to a first polysaccharide chain and via a second ether linkage to a second polysaccharide chain.
US Pat. No. 10,797,316

COATED NICKEL HYDROXIDE POWDER FOR ALKALI SECONDARY BATTERY POSITIVE ELECTRODE ACTIVE MATERIAL AND METHOD OF PRODUCING SAME

Sumitomo Metal Mining Co....

1. A method for producing a coated nickel hydroxide powder having a total carbon content of 1000 ppm by mass or less for an alkaline secondary battery positive electrode active material, the method comprising:a crystallization step in which an aqueous alkali solution is supplied to a nickel-containing aqueous solution to obtain nickel hydroxide particles crystallized out by neutralization as core particles;
a coating step in which a coating layer consisting of a cobalt compound is formed on a surface of the core particles to obtain a coated nickel hydroxide powder;
a washing step in which the coated nickel hydroxide powder is washed; and
a drying step in which the coated nickel hydroxide powder after washing is dried,
wherein in the drying step, the coated nickel hydroxide powder is dried in a decarbonated air atmosphere whose partial pressure of a carbon-containing gas is 15 Pa or less.
US Pat. No. 10,793,731

BEAD POLYMER MADE OF HARD PHASE WITH DOMAINS OF A SOFT PHASE

Evonik Operations GmbH, ...

1. A binder jetting process for the production of three-dimensional objects from a powder bed, wherein the process comprises multiple repetition of the following steps:a) application of a new powder layer on the surface of the powder bed; and
b) selective application of a binder and subsequent or simultaneous hardening of the binder in the powder bed, wherein the powder bed comprises particles, and wherein:
i) the particles comprise a PMMA suspension polymer and have an average diameter of from 30 to 110 ?m;
ii) the particles have at least two different phases, wherein the glass transition temperature of the first phase, measured by differential scanning calorimetry (DSC), is below 40° C. and the glass transition temperature of the second phase, measured by DSC, is above 70° C.
US Pat. No. 10,797,319

PRODUCTION METHOD FOR CARBONACEOUS MATERIAL FOR NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY ANODE, AND CARBONACEOUS MATERIAL FOR NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY ANODE

KUREHA CORPORATION, Toky...

1. A method for producing a carbonaceous material for a non-aqueous electrolyte secondary battery anode, the method comprising:(1) an alkali impregnating step of adding an alkali metal and/or a chemical compound containing an elemental alkali metal to a carbonaceous precursor to obtain an alkali-impregnated carbonaceous precursor;
(2) a heat treatment step of:
(a) obtaining a heat-treated product by performing main heat treatment on the alkali impregnated carbonaceous precursor at 800° C. to 1500° C. in a non-oxidizing gas atmosphere, or
(b) obtaining a heat-treated product by performing pre-heat treatment on the alkali-impregnated carbonaceous precursor at a temperature of not lower than 400° C. and lower than 800° C. in a non-oxidizing gas atmosphere and then performing main heat treatment at 800° C. to 1500° C. in a non-oxidizing gas atmosphere; and
(3) coating the heat-treated product with pyrolytic carbon, wherein
the alkali impregnating step includes a step of i) mixing the alkali metal and/or the compound containing elemental alkali metal with the carbonaceous precursor in a powder state, or ii) dissolving the compound containing elemental alkali metal in a solvent to prepare a solution of the compound containing elemental alkali metal, mixing the solution of the compound containing elemental alkali metal with the carbonaceous precursor, followed by volatilizing the solvent, so to prepare the alkali impregnated carbonaceous precursor in which the alkali metal or the compound containing elemental alkali metal is impregnated, and
the obtained carbonaceous material has a specific surface area of not greater than 10 m2/g, the specific surface area being determined by a BET method using nitrogen adsorption.
US Pat. No. 10,793,479

ACCELERATOR FOR HYDRAULIC COMPOSITION

FINE POWDER TECHNOLOGIES ...

1. A method of making a liquid hardening accelerator for a hydraulic composition, the method comprising:(a) adding sugar and lithium carbonate to water to form a dispersion of the lithium carbonate in a sugar solution;
(b) adding aluminium sulphate to the dispersion to form a liquid hardening accelerator.
US Pat. No. 10,791,689

HYBRID PLANT PRODUCTS FROM THEOBROMA SPECIES AND METHODS OF MAKING THE SAME

Mars, Incorporated, McLe...

1. A method for producing a hybrid plant or seed of Theobroma cacao and Theobroma grandiflorum, comprising:(a) crossing a variety of Theobroma cacao and a variety of Theobroma grandiflorum to obtain progeny seeds therefrom;
(b) analyzing at least a portion of the progeny seeds for
the presence of a single nucleotide polymorphism (SNP) marker indicative of a Theobroma cacao and Theobroma grandiflorum hybrid, wherein said SNP marker is w17s189(T/C), e0050s274(CAT), CIR211s1036(T/A), c3s595(C/A), w3 s41(G/T), w8s131(T/C), w3s558(A/G), or any combination thereof; and
(c) selecting one or more hybrid seeds from the progeny seeds analyzed in step (b) to produce the hybrid plant or seed.
US Pat. No. 10,793,481

METHODS FOR TREATING A PLANT EXPOSED TO A PHYTOTOXICANT

1. A method of treating a plant exposed to a phytotoxicant, said method comprising:applying a phytotoxicity-reducing amount of an assimilable carbon-skeleton energy component-comprising composition to the plant to at least ameliorate symptoms associated with exposure to the phytotoxicant, wherein the plant was exposed to the phytotoxicant by direct exposure to foliage.
US Pat. No. 10,791,690

ISOLATED POLYNUCLEOTIDES AND POLYPEPTIDES, AND METHODS OF USING SAME FOR INCREASING NITROGEN USE EFFICIENCY, YIELD, GROWTH RATE, VIGOR, BIOMASS, OIL CONTENT, AND/OR ABIOTIC STRESS TOLERANCE

Evogene Ltd., Rehovot (I...

1. A method of increasing nitrogen use efficiency, biomass, growth rate, vigor, and/or nitrogen deficiency tolerance of a plant as compared to a control plant under the same growth conditions, comprising over-expressing within the plant a polypeptide comprising the amino acid sequence as set forth by SEQ ID NO: 749, thereby increasing the nitrogen use efficiency, biomass, growth rate, vigor, and/or nitrogen deficiency tolerance of the plant.
US Pat. No. 10,796,813

CONDUCTIVE POLYMER COMPOSITE

XEROX CORPORATION, Norwa...

1. A conductive polymer composite, comprising:a thermoplastic polymer;
a plurality of multi-walled carbon nanotubes; anda plurality of metallic particulates in an amount ranging from about 55% to about 80% by weight, relative to the total weight of the conductive polymer composite,wherein the multi-walled carbon nanotubes are in an amount of at least 5% to about 20% by weight, relative to the total weight of the conductive polymer composite.
US Pat. No. 10,791,691

PAPAVER SOMNIFERUM WITH HIGH CONCENTRATION OF CODEINE

Tasmanian Alkaloids Pty. ...

1. A poppy straw from a Papaver somniferum plant, the poppy straw having a codeine fraction of about 55% by weight or greater of an alkaloid combination, and a codeine content above 0.8% by dry weight of the poppy straw, and wherein the alkaloid combination comprises morphine, codeine, thebaine and oripavine.
US Pat. No. 10,793,740

AQUEOUS POLYMER DISPERSION FOR PAPER WITH A COPOLYMER OF VINYL ACETATE AND AN ACRYLATE MONOMER PREPARED IN THE PRESENCE OF A STARCH DERIVATIVE

BASF SE, (DE)

1. A paper coating slip, comprising:an inorganic pigment, and
an aqueous dispersion comprising a polymer P, which is obtained by a process comprising:
emulsifying a mixture comprising monomers in an aqueous medium, and
polymerizing the monomers in the presence of a free-radical initiator and a starch derivative,
wherein the monomer mixture consists of:
vinyl acetate, as a monomer (a),
at least one acrylate monomer, which is selected from the group consisting of a C1-C10 alkyl acrylate and a C1-C10 alkyl methacrylate, as a monomer (b),
at least one a,ß-ethylenically unsaturated C3-C6 carboxylic acid, as a monomer (c),
at least one monomer selected from the group consisting of glycidyl methacrylate and glycidyl acrylate, as a monomer (d),
optionally at least one ethylenically unsaturated sulfonic acid, as a monomer (e), and
optionally at least one ethylenically unsaturated other monomer, which is different from the monomers (a), (b), (c), (d) and (e), as a monomer (f), and
wherein
the content of the vinyl acetate monomer (a) is from 70 to 94.7 parts by weight of the monomers,
the content of the at least one acrylate monomer (b) is from 5 to 25 parts by weight of the monomers,
the content of the at least one a,ß-ethylenically unsaturated C3-C6 carboxylic acid monomer (c) is from 0.1 to 10 parts by weight of the monomers,
the content of the at least one monomer (d) selected from the group consisting of glycidyl methacrylate and glycidyl acrylate from 0.1 to 10 parts by weight of the monomers,
the optional content of the at least one ethylenically unsaturated sulfonic acid monomer (e) is from 0.1 to 5 parts by weight of the monomers,
the optional content of the at least one other ethylenically unsaturated monomer (f) is from 0.1 to 15 parts by weight of the monomers, and
the sum total of the parts by weight of the monomers (a), (b), (c), (d), (e) and (l) is 100.
US Pat. No. 10,791,692

FINE MAPPING AND VALIDATION OF QTL UNDERLYING FIBER CONTENT AND IDENTIFICATION OF SNP MARKERS FOR MARKER ASSISTED SELECTION

Dow AgroSciences LLC, In...

1. A method for marker-assisted canola plant selection, the method comprising:crossing a first canola plant with a second, different canola plant, wherein the first canola plant is from canola line YN01-429 or its lineage or canola line YN97-262 or its lineage, and wherein the first canola plant comprises a haplotype associated with decreased fiber comprising marker alleles at a locus within the canola N09 chromosomal interval comprising and flanked by SEQ ID NO:1 and SEQ ID NO:111, thereby producing a progeny plant population; and
detecting in a plant of the progeny population the haplotype associated with decreased fiber.
US Pat. No. 10,791,693

PLANTS AND SEEDS OF CORN VARIETY CV431316

Monsanto Technology LLC, ...

1. A plant of corn variety CV431316, wherein representative seeds of corn variety CV431316 have been deposited under ATCC Accession No. PTA-126192.
US Pat. No. 10,793,742

POLYETHERS CONTAINING NON-BISPHENOLIC CYCLIC GROUPS

VALSPAR SOURCING, INC., ...

1. An article comprising a food or beverage container, or a portion thereof, having a metal substrate and a food-contact coating applied on at least a portion of the metal substrate, wherein the coating is formed from a coating composition that includes a polyether polymer having a polymer backbone, wherein the polymer contains at least two ether linkages in the polymer backbone; is substantially free of segments derived from bisphenol A and epoxides thereof; and is a reaction product of, or can be derived from, reactants including:(i) an aryl- or heteroaryl-group-containing diepoxide that is not derived from a polyhydric phenol or a glycidyl ester; and
(ii) a polymer backbone extender, wherein the extender:
(a) has two functional groups reactive with an epoxy group; and
(b) provides, following reaction with the diepoxide:
(i) at least one pendant aryl or heteroaryl group on the polymer backbone, or
(ii) at least one divalent aryl or heteroaryl group in the polymer backbone and linked to the backbone via ether linkages,
wherein the diepoxide is one or more of the diglycidyl ether of 1,2-benzenedimethanol, the diglycidyl ether of 1,3-benzenedimethanol, the diglycidyl ether of 1,4-benzenedimethanol, the diglycidyl ether of 1,4-benzenediethanol, the diglycidyl ether of 1,3-benzenedipropanol, the diglycidyl ether of 1,4-benzenedipropanol, the diglycidyl ether of 2-(4-hydroxyphenyl)ethanol, the diglycidyl ether of 4,4?-(1,4-phenylene)bis(4-methyl-2-pentanol), the diglycidyl ether of 2-(3-hydroxyphenyl)ethanol, the diglycidyl ether of 2-hydroxyphenethyl alcohol, the diglycidyl ether of 1-phenyl-1,2-propanediol, the diglycidyl ether of 2-phenyl-1,2-propanediol, the diglycidyl ether of 1-phenyl-1,3-propanediol, the diglycidyl ether of 2-phenyl-1,3-propanediol, the diglycidyl ether of 1-phenyl-1,2-ethanediol, or the diglycidyl ether of vanillyl alcohol, the diglycidyl ether of 2,5-furandimethanol.
US Pat. No. 10,791,694

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH996244

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH996244, produced by crossing a first plant of variety CV773381 with a second plant of variety CV093813, wherein representative seeds of said varieties CV773381 and CV093813 are deposited under ATCC Accession Nos. PTA-126202 and PTA-123818, respectively.
US Pat. No. 10,791,695

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH101636

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH101636, produced by crossing a first plant of variety CV447929 with a second plant of variety CV759867, wherein representative seeds of said varieties CV447929 and CV759867 are deposited under ATCC Accession Nos. PTA-126182 and PTA-124497, respectively.
US Pat. No. 10,794,000

METHODS FOR MANUFACTURING PRINTED TEXTILES

AGFA NV, Mortsel (BE)

1. A method for manufacturing printed textiles, the method comprising the steps of:inkjet printing an image onto a textile substrate with one or more inkjet printing liquids including thermally reactive composite resin particles in an aqueous medium; and
fixing the image by applying an indirect heat treatment using infrared light and/or by applying a direct heat treatment by heat convection or heat conduction to the image; wherein
the thermally reactive composite resin particles include at least one thermal cross-linker and at least one polymeric resin including functional groups suitable for reacting with the at least one thermal cross-linker; and
the at least one polymeric resin is an amphiphilic polymer including:
a hydrophobic segment that is styrene based, acrylate based, vinyl ester based, vinyl acetal based, or combinations thereof; and
a hydrophilic segment that includes at least one functional group selected from the group consisting of a sulfonic acid or salt thereof, a carboxylic acid or salt thereof, a —(CH2CH2O)n—H group wherein n represents an integer from 2 to 25, and a C2 to C12 aliphatic group substituted by hydroxyl groups wherein a carbon on hydroxyl ratio is 2 or less.
US Pat. No. 10,791,696

SOYBEAN CULTIVAR 85221631

Mertec, LLC, West Point,...

1. A plant of soybean cultivar 85221631, representative seed of said soybean cultivar having been deposited under NCMA Accession No. 201909025.
US Pat. No. 10,791,697

RICE CULTIVAR RU1401105

THE BOARD OF TRUSTEES OF ...

1. A rice seed of the variety ‘RU1401105,’ a representative sample of seed of said variety having been deposited under ATCC Accession No. PTA-126031.
US Pat. No. 10,793,489

ETHYLENE OLIGOMERIZATION PROCESSES

Chevron Phillips Chemical...

1. A process for forming an oligomer product comprising:a) introducing into a reaction zone
i. ethylene;
ii. a heteroatomic ligand;
iii. a metal salt where
1) the metal salt is an iron salt, a cobalt salt, or any combination thereof, and
2) an equivalent molar ratio of the metal salt to the heteroatomic ligand is at least 1.5:1;
iv. an organoaluminum compound wherein the organo groups of the organoaluminum compound are substantially devoid of ?,?-branched organo groups and ?,?-branched organo groups;
v. optionally hydrogen; and
vi. optionally an organic reaction medium; and
b) forming an oligomer product in the reaction zone;
wherein the oligomer product contains at least 70 weight percent products containing from 2 to 30 ethylene units.
US Pat. No. 10,794,771

COMPOSITIONS AND METHODS FOR THE DOWNCONVERSION OF LIGHT

Massachusetts Institute o...

1. A method of downconverting light, the method comprising:applying light having a first average wavelength to an organic material associated with a nanocrystal and a ligand, the organic material comprising a heteroacene, a perylene, a phthalocyanine, an oligothiophene, a furane, an anthracene, a rubrene, or a pentacene, and the nanocrystal comprising a group III-V compound, a group II-VI compound, or a group IV element, the ligand being an unsaturated organic compound having a linear carbon chain length between 5 carbon atoms and 20 carbon atoms;
transferring photons from the organic material to the nanocrystal; and
determining light emitted from the nanocrystal at a second average wavelength, wherein the second average wavelength is greater than the first average wavelength.
US Pat. No. 10,791,698

MAIZE INBRED PH47Y3

PIONEER HI-BRED INTERNATI...

1. A seed, plant, plant part, or plant cell of inbred maize variety PH47Y3, representative seed of the variety having been deposited under NCMA accession number 202006057.
US Pat. No. 10,797,333

PREPARATION METHOD FOR ALKALINE ANION EXCHANGE MEMBRANE AND USE THEREOF IN FUEL CELL

HANGZHOU DIANZI UNIVERSIT...

1. A preparation method of an alkaline anion exchange membrane, containing the steps below:1) adding a transition metal inorganic salt into deionized water, stirring, to obtain an aqueous solution of transition metal inorganic salt;
2) dissolving a polyvinyl alcohol powder into the aqueous solution of transition metal inorganic salt which is obtained in the step 1), heating and stirring, to obtain a first gel;
3) grinding an AER alkaline resin into fine powders, adding the fine powders into the first gel, after a cross-linking reaction between fine powders and the first gel, forming a second gel;
4) film-forming the second gel on a substrate, drying; and
5) alkalization pretreating the dried film.
US Pat. No. 10,791,699

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH273029

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH273029, produced by crossing a first plant of variety CV469870 with a second plant of variety CV093813, wherein representative seeds of said varieties CV469870 and CV093813 are deposited under ATCC Accession Nos. PTA-126200 and PTA-123818, respectively.
US Pat. No. 10,793,748

COATING COMPOSITION, METHOD FOR PRODUCING SAME, COATING FILM, EXHAUST FAN AND AIR CONDITIONER

MITSUBISHI ELECTRIC CORPO...

1. A coating film formed from a coating composition comprising:water;
a water-soluble organic solvent that has a flash point of at least 80° C. and not more than 200° C. and dissolves a fluorine resin;
a fluorine resin;
hydrophilic silica particles; and
hydrophobic silica particles,
wherein a thickness of the coating film is at least 0.2 ?m and not more than 3.0 ?m.
US Pat. No. 10,793,749

2-CYANOACRYLATE-BASED ADHESIVE COMPOSITION

TOAGOSEI CO., LTD., Toky...

1. A 2-cyanoacrylate-based adhesive composition comprising:(a) a 2-cyanoacrylic acid ester; and
(b) a compound having a sulfur atom-containing heteroallene structure, represented by the following Formula (1):
Rn—X?C?S  (1)
wherein X represents S O, N or C, R represents a hydrogen atom or at least one selected from the group consisting of an alkyl group having from 1 to 10 carbon atoms, a cycloalkyl group, an alkenyl group, an alkynyl group, an aralkyl group and an aryl group, each of the groups may have a substituent, n denotes 0 in a case in which X represents an S atom or an O atom, n denotes 1 in a case in which X represents an N atom, n denotes 2 in a case in which X represents a C atom, and R's may be the same as or different from each other in a case in which two R's are present.
US Pat. No. 10,793,751

PRESSURE-SENSITIVE ADHESIVE, AND SELF-ADHESIVE PRODUCTS AND COMPOSITES COMPRISING THE LATTER

TESA SE, Norderstedt (DE...

1. A block copolymer-containing pressure-sensitive adhesive comprising:a) 52 wt % to 65 wt %, of an elastomer component,
b) 30 wt % to 45 wt %, of at least one tackifier resin,
c) 0 wt % to 15 wt %, of at least one plasticizing resin, and
d) 0 wt % to 18 wt %, of further additives,
wherein the elastomer component (a) is at least 90 wt % of polyvinylaromatic-polybutadiene block copolymers, the polyvinylaromatic-polybutadiene block copolymers comprising at least one kind of a diblock copolymer (a1) and at least one kind of a triblock or multiblock copolymer (a2),
the at least one diblock copolymer (a1) has a molar mass of at least 80 000 g/mol and a vinylaromatic fraction of 20 wt % to 40 wt % and has a vinylaromatic fraction of 15 wt % to 45 wt %, within the elastomer component (a) and,
the fraction of triblock or multiblock copolymer (a2) is between 25 wt % and 50 wt %, and the triblock or multiblock copolymer (a2) has a molar mass of at least 125 000 g/mol and a vinylaromatic fraction of 15 wt % to 45 wt %, and
optionally, the one kind of the triblock or multiblock copolymer (a2) is a multiarm (radial) block copolymer,
and wherein;
the adhesives exhibit a shock resistance of greater than or equal to 180 cm in a Ball Drop test and
a peel adhesion on a steel substrate of at least 5 N/cm.
US Pat. No. 10,794,007

LOTION TREATED THROUGH-AIR DRIED TISSUE

KIMBERLY-CLARK WORLDWIDE,...

1. A treated through-air dried tissue product comprising a through-air dried tissue web having a first and an opposed second surface, a softening composition disposed on the first or the second surface, the softening composition comprising (i) from about 10 to 20 weight percent of a polyhydroxy compound selected from the group consisting of polyethylene glycols and polypropylene glycols and having a molecular weight from about 1,000 to about 10,000 g/mol (ii) from about 10 to about 20 weight percent of a cationic softener compound selected from the group consisting of amidoamine quaternary ammonium compounds, diamidoamine quaternary ammonium compounds, ester quaternary ammonium compounds, alkoxy alkyl quaternary ammonium compounds, benzyl quaternary ammonium compounds, alkyl quaternary ammonium compounds and imidazolinium compounds, and (iii) from about 40 to about 75 weight percent water, the treated through-air dried tissue product having a coefficient of friction (COF) less than about 300 g.
US Pat. No. 10,791,960

DIAGNOSIS OF ASTHMA VERSUS CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) USING URINE METABOLOMIC ANALYSIS

University of Saskatchewa...

1. A method of treating a respiratory disease in a subject comprising:a. measuring a concentration of at least 11 metabolites comprising 3-Hydroxyisovalerate, Glutamine, Arginine, Lactic acid, Glycolate, Tyrosine, 2-oxoglutarate, Glycine, Histidine, 1-methylhistamine and Taurine in a biological sample obtained from the subject to determine a subject profile;
b. comparing the subject profile, by a statistical analysis, to a predetermined asthma disease state profile and to a predetermined Chronic Obstructive Pulmonary Disease (COPD) state profile;
c. providing a diagnosis of an asthma disease state in the subject when the statistical analysis identifies the subject profile as more similar to the predetermined asthma disease state profile than to the predetermined COPD state profile; and
d. upon diagnosis of the asthma disease state, administering a treatment for asthma to the subject, wherein the treatment comprises one or more of a high dose corticosteroid and a biological therapy targeting asthmatic inflammation, and wherein the treatment does not comprise an anti-muscarinic inhaler, an antibiotic, lung surgery, or lung transplantation.
US Pat. No. 10,793,496

PROCESS FOR PRODUCING A CHLORINATED ALKANE

SPOLEK PRO CHEMICKOU A HU...

1. An industrial process for producing a C3-6 chlorinated alkane in which a chlorinated alkene or a chlorinated alkane feedstock is contacted with chlorine in a chlorination zone to produce a reaction mixture containing the C3-6 chlorinated alkane, wherein the chlorine supplied into the chlorination zone has a dissolved oxygen content of less than about 2000ppmv and wherein:the chlorination zone is closed to the atmosphere, and/or
the chlorination zone is operated under atmospheric or superatmospheric pressure, and/or
the chlorination zone is operated under an inert atmosphere, and/or
the dissolved oxygen content in the chlorinated alkene or chlorinated alkane feedstock is less than 2000 ppm,and whereinthe reaction mixture is extracted from the chlorination zone and comprises oxygenated organic compounds in amounts of about 500 ppm or less, about 250 ppm or less, about 100 ppm or less, about 50 ppm or less, about 10 ppm or less, or about 5 ppm or less.
US Pat. No. 10,796,827

CERMETS FOR MAGNETIC SENSORS

NATIONAL TSING HUA UNIVER...

1. Cermets for magnetic sensors, comprising at least six carbides and at least one refractory metal, wherein the carbides are selected from TiC, VC, ZrC, HfC, WC, NbC and TaC, the refractory metal is tungsten, the cermets for magnetic sensors operates in 100˜3000 K, and the magnetic precision is between 99.6˜99.9%.
US Pat. No. 10,797,340

LITHIUM AIR BATTERY

Hyundai Motor Company, S...

1. A lithium air battery comprising a plurality of unit cells which have different diameters, each unit cell comprises:electrodes including: a disc-shaped positive electrode having a first air flow path passing through the positive electrode in a vertical direction of the lithium air battery and one or more electrolyte flow paths on the positive electrode in a horizontal or vertical direction of the lithium air battery; and an negative electrode having a second air flow path passing through the negative electrode in the vertical direction to coincide with the first air flow path; and
a separator disposed between the positive electrode and the negative electrode,
wherein the unit cells are stacked in the vertical direction within a stack cell tank such that a diffusion layer is disposed between the respective unit cells, and
a lowermost unit cell has the greatest diameter and diameters of the remaining unit cells, which are sequentially stacked on the lowermost unit cell, gradually decreases vertically in an upward direction so that the unit cells have a stepped structure.
US Pat. No. 10,793,756

ADHESIVE COMPOSITION, ADHESIVE FILM, AND BONDING METHOD

TOKYO OHKA KOGYO CO., LTD...

1. A laminate, comprising:a wafer;
an adhesive layer formed by using an adhesive composition; and,
a support which is formed of glass or silicon,
the adhesive composition comprising;
a thermal polymerization inhibitor, and
a resin consisting of 35-100% by weight of one or more block copolymer(s) and 0-65% by weight of one or more random copolymer(s), wherein:
the block copolymer(s) each has a weight average molecular weight in a range of 50,000 to 150,000,
each of the block copolymer(s) is a diblock copolymer, a triblock copolymer, or a combination thereof, and includes a styrene group, both terminals of a main chain of the triblock copolymer are styrene groups,
a styrene group content of each of the block copolymer(s) is in a range of 10% by weight to 67% by weight, and
each of the block copolymer(s) is selected from the group consisting of styrene-butadiene-styrene block copolymer (SBS), styrene-butadiene-butylene-styrene block copolymer (SBBS), styrene-ethylene-butylene-styrene block copolymer (SEBS), styrene-ethylene-propylene-styrene block copolymer (SEPS), and styrene-ethylene-ethylene-propylene-styrene block copolymer (SEEPS);
wherein:
the adhesive composition does not comprise a plasticizer, and
the adhesive layer has a Young's modulus of 0.1 GPa or greater at 23° C., a storage modulus (G?) of 1.5×105 Pa or less at 220° C., and a loss factor (tan ?) of 1.3 or less at 220° C.
US Pat. No. 10,793,500

DISSOCIATION OF 1,4-BIS (4-PHENOXYBENZOYL)BENZENE—LEWIS ACID COMPLEX IN A PROTIC SOLVENT

ARKEMA FRANCE, Colombes ...

1. A method for manufacturing 1,4-bis(4-phenoxybenzoyl)benzene, comprising:reacting terephthaloyl chloride with diphenyl ether in the presence of a Lewis acid, so as to obtain a product mixture comprising 1,4-bis(4-phenoxybenzoyl)benzene-Lewis acid complex, wherein the 1,4-bis(4-phenoxybenzoyl)benzene-Lewis acid complex is, at least partly, in the form of a precipitate;
carrying out a solid/liquid separation of the product mixture to obtain a cake comprising the 1,4-bis(4-phenoxybenzoyl)benzene-Lewis acid complex precipitate;
putting the cake in contact with a decomplexing solvent, wherein the decomplexing solvent is a protic solvent, so as to dissociate the 1,4-bis(4-phenoxybenzoyl)benzene-Lewis acid complex into 1,4-bis(4-phenoxybenzoyl)benzene; and,
recovering the 1,4-bis(4-phenoxybenzoyl)benzene.
US Pat. No. 10,797,343

BINDER FOR ALL-SOLID-STATE SECONDARY BATTERIES, AND ALL-SOLID-STATE SECONDARY BATTERY

ZEON CORPORATION, Chiyod...

1. A binder of all-solid-state secondary batteries, comprising a binder polymer obtained by copolymerizing a monomer composition containing 5% by mass or more to 20% by mass or less of a polyalkylene oxide-based monomer and 40% by mass or more of a (meth)acrylate, andwherein the binder polymer is a copolymer containing 5% by mass or more to 20% by mass or less of a polymerization unit of the polyalkylene oxide-based monomer and 40% by mass or more of a polymerization unit of the (meth)acrylate respectively, and
the (meth)acrylate is at least one selected from an alkyl crylate, an alkoxy alkyl acrylate, a 2-(perfluoroalkyl) ethyl acrylate, an alkyl methacrylate, and a 2-(perfluoroalkyl) ethyl methacrylate.
US Pat. No. 10,793,501

METHOD FOR PROVIDING A SUCCINIC ACID SOLUTION

PURAC BIOCHEM B.V., Gori...

1. A method for providing a succinic acid solution, comprising the steps of:contacting a first magnesium succinate containing medium with a magnesium succinate concentration of 18-23 wt. % in a first acidification reactor with hydrogen chloride to form a solution of succinic acid, magnesium chloride, and hydrogen chloride, and
contacting a second magnesium succinate containing medium with a magnesium succinate concentration of 25-50 wt. % in a second acidification reactor with the solution of succinic acid, magnesium chloride, and hydrogen chloride withdrawn from the first acidification reactor, to form an aqueous mixture comprising magnesium chloride and succinic acid with a succinic acid concentration of at least 18 wt. %.
US Pat. No. 10,793,758

TWO-PACK TYPE URETHANE-BASED ADHESIVE COMPOSITION

The Yokohama Rubber Co., ...

1. A two-part urethane-based adhesive composition comprising:a main agent containing a urethane prepolymer having an isocyanate group, wherein the urethane prepolymer is produced by reacting polyoxypropylene diol, polyoxypropylene triol, and aromatic polyisocyanate; and
a curing agent containing a compound having two or more active hydrogen-containing groups in each molecule, wherein the compound having two or more active hydrogen-containing groups in each molecule includes polyoxypropylene triol or ethylene oxide/propylene oxide copolymer triol;
one of the main agent or the curing agent containing a (meth)acrylamide compound,
wherein the (meth)acrylamide compound is N-alkyl(meth)acrylamide having a hydroxy group, and the N-alkyl(meth)acrylamide having a hydroxy group is contained only in the curing agent,
wherein the N-alkyl(meth)acrylamide having a hydroxy group is N-(2-hydroxyethyl)acrylamide,
wherein a weight ratio of the main agent/the curing agent is from 10/1 to 10/8,
wherein a molar ratio of the isocyanate group contained in the urethane prepolymer to the active hydrogen-containing group contained in the compound having two or more active hydrogen-containing groups is from 0.8 to 20,
wherein a content of the (meth)acrylamide compound is from 0.01 to 3.5 mass % in the two-part urethane based adhesive composition, and
wherein the two-part urethane-based adhesive composition is cured by moisture.
US Pat. No. 10,794,527

CORROSION INHIBITION

SCHLUMBERGER TECHNOLOGY C...

1. A method of inhibiting corrosion of metal in contact with an acidic aqueous solution comprising:contacting the metal with a corrosion inhibiting composition comprising the following organic corrosion inhibiting constituents:
a water-insoluble hydrophobic material; and
a corrosion inhibitor which contains one or more polymerisable groups containing double or triple bonded carbon;
the corrosion inhibiting composition containing more than 30% by weight of the water-insoluble hydrophobic material and the corrosion inhibitor,
such that the corrosion inhibiting constituents provide both corrosion inhibitor and hydrophobic liquid, so as to form a coating of the composition on the metal surface, and
subsequently contacting the coating on the metal surface with the acidic aqueous solution which creates a polymerized hydrophobic film on the metal surface; wherein the acidic aqueous solution comprises a corrosion inhibitor which serves to maintain the polymerized hydrophobic film.
US Pat. No. 10,793,502

METHOD OF PURIFYING ACETIC ACID

SABIC GLOBAL TECHNOLOGIES...

1. A method of purifying acetic acid, comprising:passing a feed stream comprising acetic acid through a distillation column;
contacting the acetic acid with a permanganate oxidizing agent and hydrogen gas within the distillation column;
withdrawing an acetic acid product from the distillation column; and
withdrawing a gaseous product stream from a top portion of the distillation column, wherein the gaseous product stream comprises ethane, methane, carbon dioxide, oxygen, nitrogen, or a combination comprising at least one of the foregoing.
US Pat. No. 10,793,759

SULFUR- AND PHOSPHORUS-FREE EXTREME PRESSURE LUBRICANT AND PREPARATION METHOD AND APPLICATION THEREOF

YANGTZE UNIVERSITY, Jing...

1. A sulfur- and phosphorus-free extreme pressure lubricant, comprising the following raw materials: 20-30 parts by weight of Turkey red oil, 20-30 parts by weight of cyclic anhydride compound, 15-20 parts by weight of triethanolamine, 10-20 parts by weight of nano polytetrafluoroethylene powder, 5-10 parts by weight of alcohol compound, and water.
US Pat. No. 10,797,345

SULFUR COMPOUND SOLID ELECTROLYTE DISPERSION PASTE FOR SECONDARY BATTERIES, SULFUR COMPOUND SOLID ELECTROLYTE LAYER FOR SECONDARY BATTERIES USING SAME, AND ALL-SOLID-STATE SECONDARY BATTERY USING SAME

KANSAI PAINT CO., LTD., ...

1. A sulfur compound solid electrolyte dispersion paste for secondary batteries, containing a dispersion resin (A), a sulfur compound solid electrolyte (B) and a solvent (C),wherein the dispersion resin (A) contains at least one acrylic resin (a) having a weight-average molecular weight of 3000 or higher, and
wherein the acrylic resin (a) contains, as a polymerizable unsaturated monomer (a3) having a functional group, a high-polarity polymerizable unsaturated monomer (a3-1) having at least one highly polar functional group selected from the group consisting of carboxyl groups, phosphoric acid groups, sulfonic acid groups, amino groups, quaternary bases, amide groups, hydroxyl groups, polyalkylene glycol groups and alkoxy groups.
US Pat. No. 10,793,761

METALATE-BASED ADDITIVES FOR USE IN SUBTERRANEAN FORMATIONS

Halliburton Energy Servic...

1. A method comprising:providing a treatment fluid comprising a base fluid, a hydroxylic compound, and a metalate-based additive comprising an anion selected from the group consisting of: a manganate, a vanadate, and any combination thereof; and
introducing the treatment fluid into a wellbore penetrating at least a portion of a subterranean formation, wherein the treatment fluid comprises the hydroxylic compound upon introduction into the wellbore.
US Pat. No. 10,797,348

ELECTROLYTE AND LITHIUM-ION BATTERY

CONTEMPORARY AMPEREX TECH...

1. An electrolyte, comprising:an organic solvent;
a lithium salt dissolved in the organic solvent; and
an additive;
the additive comprising trifluoromethanesulfonate silyl compound, lithium fluorophosphate compound and cyclic phosphonitrile compound;
the trifluoromethanesulfonate silyl compound being one or more selected from a group consisting of trimethylsilyl trifluoromethanesulfonate, diethylmethylsilyl trifluoromethanesulfonate, triethylsilyl trifluoromethanesulfonate, trifluoromethyldimethylsilyl trifluoromethanesulfonate, tri(trifluoromethyl)silyl trifluoromethanesulfonate, dimethylethylsilyl trifluoromethanesulfonate, trivinylsilyl trifluoromethanesulfonate, triethynylsilyl trifluoromethanesulfonate and triethoxsilyl trifluoromethanesulfonate;
a content of the trifluoromethanesulfonate silyl compound being 0.1%-8% of a total weight of the electrolyte;
a content of the lithium fluorophosphate compound being 0.1%-5% of the total weight of the electrolyte;
a content of the cyclic phosphonitrile compound being 0.1%-8% of the total weight of the electrolyte; and
a content of the lithium salt being 6.25%-25% of the total weight of the electrolyte.
US Pat. No. 10,793,763

ULTRA-DRY THREE-PHASE FLUE GAS FOAM FOR OIL-GAS FIELDS AND PREPARATION METHOD THEREOF

CHINA UNIVERSITY OF PETRO...

1. An ultra-dry three-phase flue gas foam for oil-gas fields, which is produced by a gas phase, a liquid phase and a solid phase, whereinthe gas phase is a flue gas produced by a coal-fired power plant;
the liquid phase is an aqueous solution of a surfactant, a pH adjuster, and an inorganic salt;
the surfactant is a mixture of sodium a-olefin sulfonate and sodium dodecylbenzene sulfonate;
a mass ratio of the sodium a-olefin sulfonate to the sodium dodecylbenzene sulfonate is 1:4-5;
a carbon atom number of the sodium ?-olefin sulfonate is 14 to 18;
the solid phase is a mixture of fly ash and nano silica;
a foam quality of the three-phase flue gas foam is 90%.
US Pat. No. 10,793,764

LOW DENSITY CEMENTITIOUS COMPOSITIONS FOR USE AT LOW AND HIGH TEMPERATURES

HOLCIM TECHNOLOGY LTD, J...

1. A manufactured cementitious binder, comprising:a hydraulic binder in an amount in the range from 50 to 80% by weight of the cementitious binder;
a first siliceous based material in an amount in the range from 0.5 to 35% by weight of the cementitious binder, the first siliceous based material having a (SiO2)/(Al2O3) ratio by weight greater than 2.5;
a second siliceous based material in an amount in the range from 10 to 25% by weight of the cementitious binder, the second siliceous based material being different from the first siliceous based material and having (a) a (SiO2)/(Al2O3) ratio by weight greater than 10 and (b) a BET specific surface area greater than 5 m2/g, the second siliceous based material comprising a mixture of silica fume from zirconia production and another siliceous based material that is selected from the group consisting of precipitated silica, rice husk ash, and mixtures thereof;
an aluminum based material in the range greater than 0% by weight of the cementitious binder and less than 7% by weight of the cementitious binder and having a (SiO2)/(Al2O3) ratio by weight lower than 2.5,
wherein 0.09 AlEFF=molar content of aluminum in the hydraulic binder, and
SiEFF=molar content of silica in the first siliceous based material for particles having a size lower than 3 ?m+molar content of silica in the second siliceous based material, and
a lightweight additive in an amount less than 50% by weight of the cementitious binder;
wherein the cementitious binder provides a cementitious settable composition, when added with water, having a density less than 14 pounds per gallon (ppg) (1677.6 kg/m3).
US Pat. No. 10,792,228

KIT OF PARTS FOR PRODUCING A GLASS IONOMER CEMENT, PROCESS OF PRODUCTION AND USE THEREOF

3M Innovative Properties ...

1. A kit of parts for preparing a glass ionomer composition for dental use,the kit of parts comprising a Powder Part P and a Liquid Part L,
Powder Part P comprising:
acid-reactive inorganic filler,
Liquid Part L comprising:
water,
complexing or chelating agent,
polyacid,
either the Powder Part P or the Liquid Part L or the Powder Part P and the Liquid Part L comprising non-aggregated nano-sized particles based on silica or alumina, the composition obtained by combining the components of Powder Part P and Liquid Part L before hardening comprising the components in the following amounts:
non-aggregated nano-sized particles having a mean particle size in the range of 5 nm to 500 nm from 0.1 to 15 wt.-%,
acid-reactive filler in an amount from 50 to 75 wt.-%,
polyacid: 7 to 20 wt.-%,
complexing agent: 0.5 to 3 wt.-%,
water: 5 to 18 wt.-%,
wt.-% with respect to the weight of the whole composition.
US Pat. No. 10,793,508

TEREPHTHALIC ACID ESTERS FORMATION

9449710 CANADA INC., Ter...

1. A process for the transformation of a polyester selected from polyethylene terephthalate and poly(ethylene glycol-co-1,4-cyclohexanedimethanol terephthalate) into dimethyl terephthalate; the process comprising admixing the polyester with a mixture comprising:(a) methanol; and
(b) a sub-stoichiometric amount of an alkoxide;
wherein the process is performed at a temperature between about 25° C. and about 80° C.;
wherein the ratio of the polyester to the alkoxide is between about 20:1 and about 50:1 (w:w); and wherein the process achieves at least about 70% yield of dimethyl terephthalate.
US Pat. No. 10,793,765

SHALE STABILIZATION FLUIDS

Schlumberger Technology C...

1. A method, comprising:a) introducing an aqueous solution comprising i) water, ii) a shale stabilizer, iii) a surfactant, and iv) a triggering agent into a coalbed methane (CBM) well, wherein the-well comprises shale;
b) introducing an alkali silicate into the well; and
c) allowing the alkali silicate and the triggering agent to react to form a reaction product selected from the group consisting of a silicate gel, an insoluble silicate salt, and combinations thereof.
US Pat. No. 10,792,229

APERTURED FIBROUS STRUCTURES AND METHODS FOR MAKING SAME

1. A polar solvent-soluble fibrous structure comprising a plurality of polar solvent-soluble fibrous elements wherein at least one of the polar solvent-soluble fibrous elements comprises one or more fibrous element-forming materials selected from the group consisting of pullulan, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxymethyl cellulose, carboxymethyl cellulose, polyvinyl alcohol, starch, starch derivatives, polyethylene glycol, and mixtures thereof and one or more active agents present within the polar solvent-soluble fibrous element that are releasable from the polar solvent-soluble fibrous element when the polar solvent-soluble fibrous element solubilizes, the polar solvent-soluble fibrous structure further comprises a plurality of apertures wherein the apertures are arranged in a pattern within the polar solvent-soluble fibrous structure such that the polar solvent-soluble fibrous structure comprises the following structural characteristics:a. a Fiber Orientation Index Ratio of greater than 1 as measured according to the Aperture Parameter Test Method;
b. an Average Aperture Equivalent Diameter of greater than 0.15 mm as measured according to the Aperture Parameter Test Method; and
c. an Average Fractional Open Area of from about 0.005% to about 80% as measured according to the Aperture Parameter Test Method.
US Pat. No. 10,793,766

SULFOSUCCINATE SURFACTANT COMPOSITIONS AND METHODS USING THE SAME

Cytec Industries Inc., P...

1. An oil recovery surfactant system comprising:a mixture of:
(a) one or more of a first diester sulfosuccinate surfactant compound according to formula (I):
R1—O—CO—CHX—CHY—CO—O—R2  (I)
wherein:
R1 and R2 are linear or branched alkyl groups, each independently having from eight to thirteen carbon atoms,
X is —H or —SO3?M+, and
Y is —H or —SO3?M+,
when X is —H, then Y is —SO3?M+ and when Y is —H, then X is —SO3?M+, where M+ is H+, Na+, Ca+, Mg+, K+, NH4+, NR4+, where R is H, methyl, ethyl, propyl or butyl; and
(b) one or more of a first monoester sulfosuccinate surfactant compound according to formula (III):
B+?O—CO—CHX—CHY—CO—O(CH2-CH2-O)z—R5  (III)
wherein:
B+ is Na+, K+, Ca+, Mg+, NH4+, or NR4+, where R is H, methyl, ethyl, propyl or butyl,
X is as defined for formula (I),
Y is as defined for formula (I), and
Z is 0-30, and
R5 is a linear or branched alkyl group having from eight to twenty carbon atoms (C8-C20),
wherein the first diester sulfosuccinate surfactant compound is present in the surfactant system in a weight % ratio from 45 wt. % to 80 wt. % based on the total weight of the surfactant system, and the first monoester sulfosuccinate surfactant compound is present in the surfactant system in a weight % ratio from 20 wt. % to 55 wt. % based on the total weight of the surfactant system.
US Pat. No. 10,791,718

METHOD OF MAINTAINING OVARIES OF MARINE FISH, METHOD OF ADJUSTING CULTURE SOLUTION, AND METHOD OF PRODUCING EGGS OR FERTILIZED EGGS OF MARINE FISH

Nippon Suisan Kaisha, Ltd...

1. A method of maintaining ovaries of marine fish, the method comprising:removing ovaries from marine fish, wherein the ovaries comprise oocytes,
fragmenting the ovaries and conducting microplane distribution treatment immediately after the removing the ovaries from the marine fish, and
culturing the fragmented and microplane distribution treated ovaries in a culture solution,
wherein a pH of the cultured solution is adjusted to be from +0.3 to ?0.3, relative to a. pH of an ovarian cavity fluid of the marine fish from which the ovaries have been removed.
US Pat. No. 10,792,230

COMPOSITION FOR SKIN CARE

1. Cosmetic peeling cream, comprisinga) an oil-in-water emulsion, comprising
at least one fatty substance chosen from the group of fatty substances having the INCI designations Butyrospermum parkii (Shea) Butter and Helianthus annuus (Sunflower) Seed Oil in a quantity of from about 2 to about 10 wt. %, relative to the total weight of the cream,
behenyl alcohol and at least one of stearyl alcohol and cetyl alcohol, present in a total amount of from about 5 to about 10% relative to a total weight of the cream,
at least one co-emulsifier comprising a triglyceride of caprylic acid and/or caprinic acid in a quantity of from about 0.2 to about 2 wt. % relative to the total weight of the cream, and
at least one thickening agent comprising carrageenan in a quantity from about 0.5 to about 2 wt. % relative to the total weight of the cream; and
b) a peeling agent comprising sodium chloride and/or talcum powder in a quantity from about 20 to about 35 wt. % relative to the total weight of the cream;
wherein constituents a) and b) are present in a weight ratio of a) to b) of from about 4:1 to about 1:1;
wherein constituents a) and b) are present in a quantity of from about 40 to about 90 wt. % relative to the total weight of the cream,
wherein the cream further comprises water in a quantity of from about 15 to about 30 wt. % relative to the total weight of the cream;
wherein the cream has a viscosity immediately after production thereof that is at least about 70% of an initial viscosity of the a) oil-in-water emulsion before combination with the b) peeling agent; and
wherein the viscosity fluctuates less than about 5% for a period of at least about 36 hours after production.
US Pat. No. 10,793,510

METHOD FOR PREPARING ARYL SUBSTITUTED P-PHENYLENEDIAMINE SUBSTANCE

Sennics Co., Ltd., Shang...

2. A method for preparing one or more aryl substituted p-phenylenediamine compounds selected from the group consisting of N,N?-di(o-methylphenyl)-p-phenylenediamine and N-o-methylphenyl-N?-phenyl-p-phenylenediamine, comprisingreacting a reaction system consisting of nitrogen gas, a raw material A, a primer material, and a hydrogen acceptor in the presence of a supported noble metal catalyst to form the aryl substituted p-phenylenediamine compounds selected from the group consisting of N,N?-di(o-methylphenyl)-p-phenylenediamine and N-o-methylphenyl-N?-phenyl-p-phenylenediamine,
wherein the raw material A is N-phenyl-p-phenylenediamine, N-o-methylphenyl-p-phenylenediamine, or both; the primer material is cyclohexanone; the hydrogen acceptor is o-cresol; and a molar ratio of the raw material A to the primer material at the beginning of the reaction is 1:0.05 to 1:0.2.
US Pat. No. 10,797,353

METHOD OF MANUFACTURING AN ELECTROCHEMICAL CELL

GM Global Technology Oper...

1. A method of manufacturing an electrochemical cell, the method comprising:providing a porous or non-porous metal substrate;
exposing a surface of the metal substrate to a chalcogen in gas phase such that a conformal metal chalcogenide layer forms on the surface of the metal substrate;
providing a lithium metal foil having a first surface and an opposite second surface; and
laminating the lithium metal foil onto the metal chalcogenide layer on the surface of the metal substrate such that the first surface of the lithium metal foil physically and chemically bonds to the metal chalcogenide layer on the surface of the metal substrate.
US Pat. No. 10,791,719

PERUVIAN SCALLOP×BAY SCALLOP SOUTHERN SUBSPECIES HYBRID THREE-LINE BREEDING SYSTEM AND METHOD

QINGDAO AGRICULTURAL UNIV...

1. A three-line breeding, system using Peruvian scallop×Bay scallop southern subspecies hybrids, the system comprising:a male sterile line, comprising a Peruvian scallop×Bay scallop southern subspecies hybrid line that is male-sterile and yet female-fertile and spawns only eggs;
a maintainer line, comprising a Bay scallop southern subspecies line that provides sperm to fertilize eggs of the male-sterile line to produce a next generation male-sterile line; and
a restorer line, comprising a Bay scallop southern subspecies line that provides sperm to fertilize eggs of the male-sterile line to produce commercial hermaphroditic hybrid scallops.
US Pat. No. 10,792,231

LOW WATER DENTIFRICE COMPOSITIONS

Colgate-Palmolive Company...

1. A dentifrice composition comprising:an orally acceptable vehicle;
calcium pyrophosphate, wherein the calcium pyrophosphate comprises from 10 to 40% by weight of the composition;
a source of stannous ions;
a source of zinc ions, wherein the source of zinc ions comprises zinc oxide;
a source of fluoride ions;
an acid, wherein the acid is phosphoric acid; and
a polyphosphate salt selected from the group consisting of inorganic polyphosphate salts which have equal to or less than three phosphorous atoms;
wherein the polyphosphate comprises from 1 to 10% by weight of the composition;
wherein the dentifrice composition has a total water content of less than about 1% based on the weight of the composition;
wherein the source of fluoride ions and the source of stannous ions comprises stannous fluoride.
US Pat. No. 10,793,511

PROCESS FOR CONVERTING CYCLIC ALKYLENEUREAS INTO THEIR CORRESPONDING ALKYLENEAMINES

NOURYON CHEMICALS INTERNA...

1. A process for converting cyclic alkyleneureas into their corresponding alkyleneamines, the process comprising reacting a feedstock comprising cyclic alkyleneureas in the liquid phase with water in an amount of from about 0.1 to about 20 mole water per mole urea moiety, at a temperature of at least about 230° C., with removal of CO2.
US Pat. No. 10,793,768

POLYACRYLAMIDE SLURRY FOR FRACTURING FLUIDS

PfP Industries LLC, Hous...

1. A slurry composition comprising:an oil-based vehicle comprising:
a petroleum distillate,
a nonionic surfactant selected from the group consisting of a fatty chain ethylene
oxide and propylene oxide copolymer, an oxylated propoxy copolymer, and mixtures thereof,
a suspending agent comprising a linear diblock copolymer based on styrene and
ethylene/propylene, and
no white medicinal oil, and
a water-soluble polymer comprising water-soluble polyacrylamide particles, wherein:
the particles become coated with the petroleum distillate and the surfactant in the slurry,
the coating reduces particle-to-particle cohesion,
the suspending agent suspends the coated polyacrylamide particles in the oil-based vehicle
and reduces particle settling, and
when the slurry is exposed to a water source in the presence of a proppant to form a
fracturing fluid, the coating improves hydration rates and the oil-based vehicle improves
proppant carrier properties and reduces friction properties of the fracturing fluid.
US Pat. No. 10,792,232

METHODS TO DELIVER ANTIFIBRINOLYTIC DRUGS FOR ANTI-AGING RESULTS

MURDOCK TECHNOLOGIES, LLC...

1. A method to treat the skin aging effects of one or more of lines and wrinkles of a human individual, the method comprising selecting a target area of the skin to be treated, countering plasmin activity of the fibrinolytic process by administering an antifibrinolytic agent to the individual in a dosage of less than six grams per day, and thereby reducing one or more of the skin aging effects of the target area treated as compared with that target area prior to treatment.
US Pat. No. 10,791,721

WW HOMOGAMETIC MALE DECAPOD CRUSTACEAN AND METHODS OF USING THE SAME

ENZOOTIC HOLDINGS LTD., ...

1. A WW homogametic male decapod crustacean.
US Pat. No. 10,791,722

POPULATION CONTROL USING ENGINEERED TRANSLOCATIONS

CALIFORNIA INSTITUTE OF T...

1. A translocation mediated gene drive system, the gene drive system comprising:a first construct, configured to be positionable at a first insertion site in a first chromosome, wherein the first construct comprises:
a) a first location to insert a first gene of interest;
b) a first promoter;
c) a first fragment of foreign stuffer DNA;
d) a second fragment of foreign stuffer DNA;
e) a first target site of a pair of target sites for an endonuclease positioned between the first and second fragments of foreign stuffer DNA;
f) a first splice acceptor site, positioned downstream from a-e; and
g) a first splice donor site, positioned between b and c, and
a second construct, configured to be positionable at a second insertion site in a second chromosome, wherein the second construct comprises:
h) a second location to insert a second gene of interest;
i) a second promoter;
j) a third fragment of foreign stuffer DNA, wherein the third fragment is homologous to the second fragment;
k) a fourth fragment of foreign stuffer DNA, wherein the fourth fragment is homologous to the first fragment;
l) a second target site of the pair of target sites for an endonuclease positioned between the third and fourth fragments of foreign stuffer DNA;
m) a second splice acceptor site, positioned downstream from h-l, and
n) a second splice donor site, positioned between i and j,
wherein the first and second chromosomes are non-homologous chromosomes,
wherein the first fragment of foreign stuffer DNA is homologous to the fourth fragment of foreign stuffer DNA and the second fragment of foreign stuffer DNA is homologous to the third fragment of foreign stuffer DNA,
wherein a double stranded break created at the first, and second target sites of the pair of target sites allows for homologous recombination between the first and fourth fragments, and between the second and third fragments upon a repair of the double stranded break (DSB),
wherein the repair of the DSB induces a chromosomal translocation and generates a first translocation chromosome and a second translocation chromosome.
US Pat. No. 10,793,771

PHOSPHOR FILM

CITIZEN ELECTRONICS CO., ...

1. A phosphor film comprising:phosphor particles;
a thermally-conductive filler comprising glass particles and/or alumina particles; and
a binder bonding the phosphor particles and the thermally-conductive filler together,
wherein the binder is a thermosetting resin and starts to cure at a temperature that is in a range of 20 degrees to 300 degrees, and
wherein a weight ratio of a weight of the binder to a total weight of the phosphor particles and the thermally-conductive filler is in a range of 0.1 wt % to 5.0 wt %.
US Pat. No. 10,792,235

TRANSPARENT OILY SOLID COSMETICS

Kokyu Alcohol Kogyo Co., ...

1. A transparent oily solid cosmetic comprising transparent gelling agents which comprise dibutyl lauroyl glutamide and dibutyl ethylhexanoyl glutamide; an oil agent having a refractive index of 1.460 or more at 20° C.; an oil agent selected from the group consisting of ethylhexyl isononanoate, isotridecyl isononanoate, isononyl isononanoate and isodecyl neopentanoate; isostearic acid, wherein the content of isostearic acid is 5.0-30.0 wt %; and 12-hydroxystearic acid, wherein the content of 12-hydroxystearic acid is 2.0-10.0 wt %.
US Pat. No. 10,792,236

DENTIFRICE COMPRISING ZINC-AMINO ACID COMPLEX

Colgate-Palmolive Company...

1. A dentifrice comprising a zinc-amino acid-halide complex, wherein the amino acid is lysine, and complex is a zinc lysine chloride complex having the chemical structure [Zn(C6H14N2O2)2Cl]+ Cl?, either in solution of the cationic cation [Zn(C6H14N2O2)2Cl]+ and the chloride anion, or in solid salt form, optionally in mono- or dihydrate form, wherein the composition comprises one or more alkali phosphate salts.
US Pat. No. 10,792,237

AQUEOUS SURFACTANT COMPOSITIONS

BASF SE, Ludwigshafen (D...

1. An aqueous surfactant composition comprising:(a) two or more alpha-sulfo fatty acid disalt (A) of general formula (I),
R1CH(SO3M1)COOM2  (I),
in which (i) radical R1 is a saturated, linear alkyl radical with 10 to 16 carbon atoms, at least some of R1 is a decyl radical, at least some of R1 is a dodecyl radical, and the fraction of the compound (A) in which the radical R1 is the decyl or the dodecyl radical based on the total amount of the compound (A) is 90% by weight or more, and (ii) radicals M1 and M2, independently of one another, are selected from the group consisting of H, Li, Na, K, Ca/2, Mg/2, ammonium, and alkanolamine,
(b) one or more amidoalkylbetaine (B) of general formula (II),
R2—CO—NH—(CH2)y—N+(CH3)2—CH2—COO?  (II),
in which radical R2 is a linear or branched alkyl or alkenyl radical with 7 to 19 carbon atoms and the index y is an integer in the range 2 to 4,
(c) one or more compound (C) of general formula (III),
R4COOM3  (III),
in which the radical R4 is a linear or branched alkyl or alkenyl radical with 7 to 19 carbon atoms and the radical M3 is selected from the group consisting of H, Li, Na, K, Ca/2, Mg/2, ammonium, and alkanolamine,
(d) one or more inorganic salt of sulfuric acid (D) of general formula (IV),
(M4)2SO4  (IV),
wherein M4 is selected from the group consisting of Li, Na, K, Ca/2, Mg/2, ammonium, and alkanolamine, and
(e) water,
where the following provisos apply:
the aqueous surfactant composition is free from one or more ester sulfonate (E) of the general formula (V),
R5CH(SO3M5)COOR6  (V),
in which radical R5 is a linear or branched alkyl or alkenyl radical with 6 to 18 carbon atoms and radical R6 is a linear or branched alkyl or alkenyl radical with 1 to 20 carbon atoms, and the radical M5 is selected from the group consisting of Li, Na, K, Ca/2, Mg/2, ammonium, and alkanolamines;
the aqueous surfactant composition is free from additional surfactants having an alkoxy group other than components (A)-(D);
with regard to the compound (B), it is the case that the fraction of the compound (B) in which the radical R2 is an alkenyl radical, based on the total amount of the compound (B) in the aqueous surfactant composition, is 3% by weight or less;
the content of the compounds (A) and (B) in the aqueous surfactant composition is, based on the total aqueous surfactant composition, at least 5% by weight;
a weight ratio of the compounds (A):(B) in the aqueous surfactant composition is in the range from 1:1.5 to 1:5;
the content of (A) is in the range from 60 to 100% by weight based on the sum of compounds (A), (C), and (D) in the aqueous surfactant composition;
the content of (C) is in the range from more than 0 to 20% by weight based on the sum of compounds (A), (C), and (D) in the aqueous surfactant composition;
the content of (D) is in the range from more than 0 to 20% by weight based on the sum of compounds (A), (C), and (D) in the aqueous surfactant composition;
a pH of the aqueous surfactant composition is 5.8 or less;
a viscosity of the aqueous surfactant composition, measured using a Brookfield RV laboratory rheometer at 23° C., 12 rpm, spindle set RV 02 to 07 (spindle choice depending on viscosity range), is 1000 mPas or higher; and
an average transmission of the aqueous surfactant composition at 23° C., measured using a TurbiScan MA 2000, is at least 80%.
US Pat. No. 10,793,517

PROCESS FOR PRODUCING TAURINE

Vitaworks IP, LLC, North...

1. A process for producing taurine from ammonium isethionate, comprising:(a) preparing an ammonia solution comprising ammonium isethionate and at least one hydrogenation catalyst;
(b) subjecting the ammonia solution to an ammonolysis reaction in the presence of hydrogen or at least one hydrogen donor to yield a solution comprising ammonium taurinate;
(c) removing ammonia and decomposing the ammonium taurinate to taurine by heating to obtain a crystalline suspension of taurine; and
(d) separating the taurine by means of a solid-liquid separation to obtain a mother liquor.
US Pat. No. 10,793,774

PHOSPHOR, METHOD FOR PRODUCING A PHOSPHOR AND USE OF A PHOSPHOR

OSRAM OLED GMBH, Regensb...

1. Phosphor of the formula AE16?xCexSi17-zAlzN32+y?zO2?y+z with AE=Mg, Ca, Sr and/or Ba, 0
US Pat. No. 10,796,849

MAGNETICALLY TUNABLE PHOTONIC CRYSTALS BASED ON ANISOTROPIC NANOSTRUCTURES

THE REGENTS OF THE UNIVER...

1. A method of forming magnetically tunable photonic crystals comprising:synthesizing precursory nanoparticles with anisotropic shapes, the anisotropic precursory nanoparticles being iron oxyhydroxide (FeOOH) nanorods;
coating the anisotropic precursory nanoparticles with silica to form composite structures;
converting the anisotropic precursory nanoparticles into magnetic nanomaterials through chemical reactions, the chemical reactions including reducing the coated composite structure with reducing agents to render the coated composite structures magnetic; and
assembling the anisotropic magnetic nanoparticles into photonic crystals in a solvent.
US Pat. No. 10,792,239

WHITE KERATIN COMPOSITIONS

Kernnetics, Inc., Winsto...

1. A method of making a composition comprising keratose, said method comprising:(a) bleaching a keratin protein source with an oxidizing bleaching agent to produce a bleached keratin protein source;
(b) removing the bleaching agent from the bleached keratin protein source;
(c) oxidizing the bleached keratin protein source of (b); and
(d) extracting keratose from the oxidized keratin protein source of (c),
wherein said composition comprises the keratose extracted at (d),
wherein a dried form of the composition is white in the absence of added colorants or additives, and
wherein a solution form of the composition is colorless, said solution form comprising the keratose and a solvent.
US Pat. No. 10,793,777

LOW DENSITY CLOSED CELL COMPOSITE AEROGEL FOAM AND ARTICLES INCLUDING SAME

LUKLA INC., Cincinnati, ...

1. A composite foam comprising:silica aerogel particles dispersed in a closed cell polymeric foam,
wherein the composite foam includes the silica aerogel particles in a volume fraction between 2 and 60%, and has a thermal conductivity of 40 kW/mK or less and a density of 60 kg/m3 or less, and is perforated with an air permeability of 5-60 cubic feet per minute.
US Pat. No. 10,793,521

CRYSTALLINE FORM II OF DEXTRAL OXIRACETAM, PREPARATION METHOD THEREFOR AND USE THEREOF

CHONGQING RUZER PHARMACEU...

1. A crystalline form II of dextral oxiracetam having diffraction peaks at diffraction angles 2? of 14.14±0.2°, 17.76±0.2°, 18.72±0.2°, 20.16±0.2°, 21.20±0.2°, 21.52±0.2°, 24.17±0.2° and 25.88±0.2°.
US Pat. No. 10,791,730

COMPOSITION AND METHODS FOR CRYOPRESERVATION OF HUTC

DEPUY SYNTHES PRODUCTS, I...

1. A composition comprising umbilical cord tissue-derived cells and a cryopreservation medium, wherein said cryopreservation medium comprises:the amino acids L-Arginine, L-Glutamine, Glycine, L-Isoleucine, L-Leucine, L-Lysine HCl, L-Methionine, L-Phenylalanine, L-Serine, L-Threonine, L-Tryptophan, and L-Valine;
the vitamins D-calcium pantothenate, choline chloride, folic acid, niacinamide, pyridoxine HCl, riboflavin and thiamine HCl;
the inorganic salts potassium chloride, sodium bicarbonate, sodium chloride, and sodium phosphate monobasic H2O;
the inorganic salts calcium chloride dihydrate, magnesium chloride, potassium bicarbonate, and potassium monophosphate; and
lactobionic acid, glutathione, dextrose, sucrose, mannitol, and from about 5 to about 10% v/v of DMSO,
wherein the composition lacks serum, and
wherein the composition comprises about 3.2 mg/L of calcium chloride dihydrate, about 458 mg/L of magnesium chloride, about 225 mg/L of potassium bicarbonate, and about 612 mg/L of potassium monophosphate.
US Pat. No. 10,792,242

METHOD FOR REDUCING SKIN SAGGING AND/OR IMPROVING SKIN BRIGHTNESS BY USING GUM TRAGACANTH COMPOSITION

TCI CO., LTD., Taipei (T...

1. A method for treating skin sagging of a human in need thereof consisting essentially of administering via a patch a therapeutically effective amount of gum tragacanth, propanediol, and glycerol to effectively reduce the sagginess of the skin of the human in need thereof.
US Pat. No. 10,791,731

METHODS FOR PREPARING FROZEN PLASMA MATERIAL FOR RAPID THAWING IN AN EMERGENCY SITUATION

The Regents of the Univer...

1. A method for preparing a frozen bag of plasma material for rapid thawing at a site of a patient in need of urgent administration of the plasma material comprising:positioning a bag of plasma material in a support container configured to encapsulate and protect the bag of plasma material;
positioning the support container in a freezer for a time of at least 12 hours in order to freeze the plasma material; and
applying a compression force on the support container before the plasma material begins to freeze and during the time of freezing to compress the bag of plasma material to achieve a flat bag of frozen plasma material having a uniform thickness of less than or equal to 1.3 cm;
wherein the compression force is an active external force supplied independent of the support container and is distributed uniformly across the bag to flatten the bag of plasma material.
US Pat. No. 10,791,987

METHODS AND SYSTEMS FOR MANAGING A RISK OF MEDICATION DEPENDENCE

1. A method of delivering a medication to a patient using an estimated time until the patient will become dependent on the medication, the method comprising:a) recording, via processing circuitry, a medication log including dose information and time information for a plurality of administrations of the medication;
b) determining, via the processing circuitry, a conservative estimate of the time until the patient will become dependent on the medication based on at least the medication log, a pharmacokinetic model, and a model of medication tolerance, the conservative estimate corresponding to a time at which a patient's effect site concentration will be equal to or less than an estimated effect site concentration at which medication withdrawal can occur for the patient; and
c) sending, via the processing circuitry, a signal to a single-dose medication dispenser being in a locked state when the conservative estimate is greater than a predetermined threshold, the signal unlocking a single dose of the medication from the single-dose medication dispenser.
US Pat. No. 10,792,243

HONEY COMPOSITIONS

Honeylab Limited, Wellin...

1. A sealed container consisting essentially of a composition consisting essentially of:from about 85% w/w kanuka honey to about 95% w/w kanuka honey; and
from about 5% w/w glycerine to about 15% w/w glycerine.
US Pat. No. 10,791,732

WATER DISPERSIBLE GRANULAR COMPOSITION

DEEPAK PRANJIVANDAS SHAH,...

33. A synergistic water dispersible granular composition for spray application comprising:a micronized agrochemically active granule comprising at least one micronized solid agrochemically active substance in the range of 0.1% to 45% w/w; wherein the granule itself is composed of the micronized solid agrochemically active substance; and
an agrochemically active formulation absorbed to the micronized agrochemically active granule, the formulation comprising at least one liquid or low melting agrochemically active substance in the range of 0.1% to 25% w/w;
wherein the water dispersible granular composition remains in suspension for spray application and forms a stable suspension in water and exhibits a suspensibility equal to or greater than 70 percent;and wherein:(a) the solid agrochemically active substance is imidacloprid and the liquid or low melting agrochemically active substance is lambda cyhalothrin;
(b) the solid agrochemically active substance is fipronil and the liquid or low melting agrochemically active substance is lambda cyhalothrin;
(c) the solid agrochemically active substance is thiamethoxam and the liquid or low melting agrochemically active substance is cypermethrin;
(d) the solid agrochemically active substance is imidacloprid and the liquid or low melting agrochemically active substance is chlorpyrifos;
(e) the solid agrochemically active substance is fipronil and the liquid or low melting agrochemically active substance is chlorpyrifos;
(f) the solid agrochemically active substance is deltamethrin and the liquid or low melting agrochemically active substance is chlorpyrifos;
(g) the solid agrochemically active substance is tebuconazole and the liquid or low melting agrochemically active substance is lambda cyhalothrin;
(h) the solid agrochemically active substance is azoxystrobin and the liquid or low melting agrochemically active substance is lambda cyhalothrin; or
(i) the solid agrochemically active substance is azoxystrobin and the liquid or low melting agrochemically active substance is propiconazole.
US Pat. No. 10,792,244

PARENTERAL SUSTAINED-RELEASE DELIVERY OF CARVEDILOL DISPERSE SYSTEMS

ASCENDIA PHARMACEUTICALS,...

1. A parenteral drug delivery composition for sustained release, comprising:carvedilol encapsulated inside microparticles or nanoparticles forming liposomes,
wherein the liposomes contain approximately 0.047% of the carvedilol,
wherein the liposomes are in a size range of 0.05 microns to 0.3 microns in diameter,
wherein the liposomes provide a longer residence time of the carvedilol in vivo, as compared to a free-carvedilol solution administered parenterally, and
wherein the liposomes exhibit an in vitro release of greater than 80% of total drug for a minimum of 2 hours and an in vitro release of 80% of total drug for a minimum of 6 hours.
US Pat. No. 10,793,524

METHOD FOR PRODUCING AROMATIC NITRILE COMPOUND AND METHOD FOR PRODUCING CARBONIC ACID ESTER

MITSUBISHI GAS CHEMICAL C...

1. A method for producing an aromatic nitrile compound, comprising:a dehydration reaction of dehydrating an aromatic amide compound;
wherein the dehydration reaction uses a solvent comprising one or a plurality of substances selected from 1,2-dimethoxybenzene, 1,3-dimethoxybenzene and 1,3,5-trimethoxybenzene.
US Pat. No. 10,791,733

MULTI-PURPOSE PROTECTANT COMPOSITIONS AND METHODS COMPRISING AN ORGANOSILANE WITH HYDROLYZABLE GROUPS

Hyper Green Holdings, LLC...

1. A multi-purpose protectant composition, the protectant composition comprising an aqueous mixture of:an organosilane with hydrolyzable groups;
a surfactant; and
an additive; and
water;
wherein the organosilane is selected from the group consisting of 3-(trimethoxysilyl) propyl octadecyl dimethyl ammonium chloride, 3-(trihydroxysilyl) propyl methylphosphonate monosodium, (3-N, N-dimethyl-3-N-n-octylammoniopropyl) trimethoxysilane chloride, 3(trihydroxysilyl) propyldimethyl octadecyl ammonium chloride, (3-N, N, N-triethanolammoniopropyl) trimethoxysilane chloride, (3-glycidoxypropyl) diethoxysilane, (3-N, N-dimethyl-3-N-n-hexadecylammoniopropyl) trimethoxysilane chloride, and combinations thereof; and
wherein the additive is selected from the group consisting of citranellol, capsaicinoid, 3-[N-butyl-N-acetyl]-aminopropionic acid, ethyl ester, para-menthane-3,8-diol, 2(2-hydroxyethyl)-1-piperidinecarboxylic acid 1-methylpropyl ester, N,N-diethyl-m-toluamide, N,N-diethyl-3-methyl-benzamide, tea tree oil, lemon oil, eucalyptus oil, and combinations thereof.
US Pat. No. 10,792,245

ANTIMICROBIAL POLYMER FOR USE IN OPHTHALMIC IMPLANTS

Keramed, Inc., Irvine, C...

1. An ophthalmic implant comprising an antimicrobial polymer, comprising:at least one antimicrobial monomer, wherein the antimicrobial monomer is a quaternary ammonium salt based monomer selected from 1-[12-(methacryloyloxy)dodecyl]-pyridinium bromide (MDPB), methacryloxylethyl cetyl dimethyl ammonium chloride (DMAE-CB), 2-methacryloxyethyl dodecyl methyl ammonium bromide (MAE-DB), 2-methacryloxyethyl hexadecyl methyl ammonium bromide (MAE-HB), and bis(2-methacryloxyethyl) dimethyl ammonium bromide (IDMA-1); and,
at least one other monomer selected from an acrylic, vinyl and collagen monomer; and,
wherein the ophthalmic implant is an intraocular lens.
US Pat. No. 10,793,782

SOLVENT FOR USE IN AROMATIC EXTRACTION PROCESS

SAUDI ARABIAN OIL COMPANY...

1. A process for the separation of aromatic hydrocarbon compounds from a mixture of hydrocarbons, the process comprising:a. contacting the mixture containing both aromatic and non-aromatic hydrocarbon compounds with an ODSO aromatic extraction solvent one or more of the following compounds:
1,2 alkyl-alkyl-disulfane 1,1,2 trioxide (R-SOO-SO-R),
1,2 alkyl-alkyl-disulfane 1,1,2,2 tetraoxide (R-SOO-SOO-R),
alkyl-sulfoxidesulfonate (R-SO-SOO-OH),
alkyl-sulfonesulfonate (R-SOO-SOO-OH),
alkyl-sulfoxidesulfinate (R-SO-SO-OH), and
alkyl-sulfonesulfiante (R-SOO-SO-OH) to form an extract containing the solvent and dissolved aromatics, and a raffinate comprising non-aromatic hydrocarbon compounds;
b. separating the extract from the raffinate; and
c. recovering a hydrocarbon stream of reduced aromatic content and an extract stream.
US Pat. No. 10,792,246

FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM

BIOXCEL THERAPEUTICS, INC...

1. A self-supporting, dissolvable, mucoadhesive film for sublingual administration comprising:(i) dexmedetomidine or a pharmaceutically acceptable salt thereof;
(ii) a first water-soluble hydroxypropyl cellulose polymer having a molecular weight of about 40,000 daltons;
(iii) a second water-soluble hydroxypropyl cellulose polymer having a molecular weight of about 140,000 daltons;
(iv) a third water-soluble hydroxypropyl cellulose polymer having a molecular weight of about 370,000 daltons; and
(v) a water-soluble polyethylene oxide polymer having a molecular weight of about 600,000 daltons;
wherein: the only polymers present in the film are water-soluble hydroxypropyl cellulose and water-soluble polyethylene oxide polymers; said first water-soluble hydroxypropyl cellulose polymer having a molecular weight of about 40,000 daltons is present at about 3% to about 8% w/w of the total film weight; said second hydroxypropyl cellulose polymer having a molecular weight of about 140,000 daltons is present at about 3% to about 8% w/w of the total film weight and said third water-soluble hydroxypropyl cellulose polymers having a molecular weight of about 370,000 daltons is present at about 20% to about 40% w/w of the total film weight; said water-soluble polyethylene oxide polymer having a molecular weight of about 600,000 daltons is present at about 50% to about 60% w/w of the total film weight; the polymers in (ii), (iii), (iv) and (v) above together form a single layer film substrate; and
dexmedetomidine or a pharmaceutically acceptable salt thereof is present on one surface of said single layer film substrate.
US Pat. No. 10,795,065

SOLAR-RADIATION-SHIELDING MATERIAL FOR VEHICLE WINDOW AND WINDOW FOR VEHICLE

Sumitomo Metal Mining Co....

1. solar-radiation-shielding material for vehicle windows, the solar-radiation-shielding material comprisinga polycarbonate resin that includes fine particles having a heat-ray-shielding function, the fine particles consisting of a mixture of
a surface oxidized titanium nitride that includes a surface modified with methylsilane [MeSi(O-)3];
a composite tungsten oxide defined by a general formula: CayWOz (0.001 ?Y?1.0, and 2.2?Z?3.0); and
Fe2O3;
the solar-radiation-shielding material having a visible light transmittance in the range of 5% to 40%; having a ratio of solar radiation transmittance to visible light transmittance of less than 1; having a transmission color within the range of ?2
US Pat. No. 10,796,857

INORGANIC/ORGANIC HYBRID PEROVSKITE COMPOUND FILM, AND METHOD FOR MANUFACTURING SAME

KOREA RESEARCH INSTITUTE ...

1. An inorganic/organic hybrid perovskite compound film, being a polycrystal, and having a discontinuous (100) plane scattering intensity, at which (100) plane diffraction does not occur in all directions and a diffraction peak occurs only at a specific azimuth, on a grazing incidence wide angle X-ray scattering (GIWAXS) spectrum using an X-ray wavelength of 1.0688 ?.
US Pat. No. 10,792,247

ORAL TRANSMUCOSAL COMPOSITIONS INCLUDING AROMATASE INHIBITORS FOR LOW TESTOSTERONE LEVELS IN MEN

Professional Compounding ...

1. A method of oral transmucosal delivery of aromatase inhibitors into a patient's bloodstream consisting of:administering to the patient a composition consisting of:
(a) about 0.25 to about 2.5 mg letrozole;
(b) about 1-5% gelatin;
(c) about 1-5% pectin;
(d) about 1-10% sodium carboxymethylcellulose;
(e) about 0.1-5% xanthan gum;
(f) 1-10% polyethyleneglycol;
(g) a penetration enhancer; and
(h) a plasticized base.
US Pat. No. 10,791,736

CONFIGURATIONAL STEREOISOMER OF DIFETHIALONE, COMPOSITION AND RODENTICIDAL BAIT COMPRISING SAME, AND PROCESS FOR CONTROLLING TARGET RODENT PESTS

LIPHATECH, Pont-du-Casse...

1. Rodenticidal bait comprising at least one excipient that is edible for target rodent pests and a rodenticidal amount of difethialone in the form of a dextrorotatory enantiomer of a configurational stereoisomer of difethialone, named homo-stereoisomer, the formula of which is 3-(4?-bromobiphenyl-4-yl)-1-(4-hydroxythiocoumarin-3-yl)-1,2,3,4-tetrahydronaphthalene, in which carbons 1 and 3 of the 1,2,3,4-tetrahydronaphthalene group of said homo-stereoisomer have the same absolute configuration, with the exclusion of a racemic mixture of the dextrorotatory and laevorotatory enantiomers of said homo-stereoisomer of difethialone, and the rodenticidal bait comprising an amount of the dextrorotatory enantiomer of said homo-stereoisomer of difethialone such that the ratio of this amount to the amount of difethialone in the rodenticidal bait is greater than 90%.
US Pat. No. 10,791,992

SYSTEM AND METHOD FOR MULTI-PARAMETER CHARACTERIZATION OF BIOLOGICAL TISSUES

University of Maryland, ...

20. A method of using the measurement system of claim 1, the method comprising:moving the indenter of the micro-indentation mechanism from the initial position to the sensing position to operatively couple the tissue sample to said tissue sample receiving chamber and to sandwich the tissue sample between the biochip and the indenter to establish the substantially contiguous contact between said biochip and the tissue sample;
executing said measurement routine to produce the plurality of multi-parameter measurement signals to characterize the two or more of electrical, mechanical, and thermal properties of the tissue sample; and
processing said plurality of measurement signals for the biological tissue- or cancer-sample characterization.
US Pat. No. 10,792,248

AQUEOUS SUSPENSION PREPARATION COMPRISING NANOPARTICLES OF MACROLIDE ANTIBACTERIAL AGENT

ACTIVUS PHARMA CO., LTD.,...

1. An aqueous suspension formulation comprising:nanoparticles consisting essentially of a macrolide antibiotic; and
a dispersion stabilizer comprising polyoxyethylene hydrogenated castor oil,
wherein the nanoparticles have an average particle diameter of 500 nm or less and a 90% diameter of 1500 nm or less.
US Pat. No. 10,793,785

HYDROCRACKING CATALYST BASED ON HIERARCHICALLY POROUS BETA ZEOLITE AND METHOD OF PREPARING THE SAME AND METHOD OF PREPARING BIO-JET FUEL FROM TRIGLYCERIDE-CONTAINING BIOMASS USING THE SAME

KOREA ADVANCED INSTITUTE ...

1. A hydrocracking catalyst based on hierarchically porous beta-zeolite, comprising:(A) a hierarchically porous beta-zeolite support which has a specific surface area of 789 to 850 m2g?1, an external surface area of 316 to 400 m2g?1, a mesopore volume of 1.14 to 1.5 cm3g?1, and a total pore volume of 1.36 to 2.0 cm3g?1; and
(B) a metallic component supported in the support.
US Pat. No. 10,791,737

SOYBEAN DISEASE CONTROL COMPOSITION AND SOYBEAN DISEASE CONTROL METHOD

ISHIHARA SANGYO KAISHA, L...

1. A method for controlling a soybean disease, which comprises applying a soybean disease control composition containing active ingredients, wherein the active ingredients in the soybean disease control composition consist of (a) fluazinam or a salt thereof and (b) at least one fungicide selected from the group consisting of imazalil, pefurazoate, and ipconazole, to a soybean plant or soil.
US Pat. No. 10,791,738

COMPOSITION AND METHOD FOR PROTECTING PLANT AGAINST DISEASE AND PEST

SUMITOMO CHEMICAL COMPANY...

1. A composition comprising fluopyram and fluxapyroxad, wherein a weight ratio of fluopyram to fluxapyroxad is within a range of 1:0.01 to 1:10.
US Pat. No. 10,792,250

METHODS FOR FORMING MINIEMULSIONS AND USE THEREOF FOR DELIVERING BIOACTIVE AGENTS

NS TECHNOLOGIES PTY LTD, ...

1. A method for forming a delivery system for a lipophilic bioactive agent comprising the following sequential steps;a. preparing a first phase by:
(i) dissolving a hydrophilic surfactant in water above critical micelle concentration (CMC) to produce an aqueous phase; and then
(ii) dispersing lipophilic surfactant in said aqueous phase to produce said first phase which first phase contains micelles of hydrophilic surfactant and lipophilic surfactant and comprises a multi-lamellar structure;
b. preparing a second phase comprising lipid and a lipophilic bioactive agent; and
c. adding the second phase to the first phase drop-wise or as a continuous flow or continuous stream during continuous mixing at a speed of between about 5,000 rpm and about 20,000 rpm, at a temperature of 40° C. or less and at an atmospheric pressure of less than 1,000 kPa to form a miniemulsion comprising between about 0.5% w/w and about 5% w/w hydrophilic surfactant, between about 1% w/w and about 5% w/w lipophilic surfactant, between about 0.5% w/w and about 25% w/w lipid, and between about 0.2% w/w and about 5% w/w lipophilic bioactive agent; and
wherein said delivery system comprises emulsified particles having a mean diameter of between 250 nm and 1 ?m which are stable for 3 months or more between 2° C. and 30° C.
US Pat. No. 10,792,251

LIPOSOMAL PARTICLES, METHODS OF MAKING SAME AND USES THEREOF

NORTHWESTERN UNIVERSITY, ...

12. A method for treating cancer, comprising administering to a patient a plurality of liposomal particles, each liposomal particle having a substantially spherical geometry and a lipid bilayer comprising a plurality of lipid groups, and about 10-40 oligonucleotides on the external side of the lipid bilayer, wherein all oligonucleotides are single-stranded, wherein each oligonucleotide is a toll-like receptor 9 (TLR9) agonist, wherein each oligonucleotide is an oligonucleotide-lipid conjugate containing one lipophilic tethered group, wherein each lipophilic tethered group is adsorbed into the lipid bilayer, wherein said plurality of liposomal particles has a mean diameter of less than or equal to about 40 nanometers (nm), and wherein the administering treats the cancer.
US Pat. No. 10,792,252

HIGHLY CONCENTRATED POWDERED OLEORESIN COMPOSITION AND PROCESS FOR PREPARATION THEREOF

Vivek Anand Parachur, Ch...

1. A tablet or capsule consisting essentially of:an oleoresin selected from the group consisting of a clove oleoresin, a curry leaf oleoresin, a pepper oleoresin, a cardamom oleoresin, a chili oleoresin, a capsicum oleoresin, a paprika oleoresin, a ginger oleoresin, a curcuma xanthorrhiza oleoresin, a turmeric oleoresin, a coriander oleoresin, a cumin oleoresin, a celery oleoresin, a dill oleoresin, a fenugreek oleoresin, a garlic oleoresin, a mace oleoresin, a garcinia extract, a fennel oleoresin, a tamarind oleoresin, a cinnamon oleoresin, a nutmeg oleoresin, a cassia oleoresin, a galangal oleoresin, a parsley oleoresin, a thyme oleoresin, a marigold oleoresin, a rosemary oleoresin, a mustard oleoresin, a curry powder oleoresin, a vanilla oleoresin, and mixtures thereof;
a first compound selected from the group consisting of calcium hydroxide, magnesium hydroxide, zinc hydroxide, iron hydroxide, aluminium hydroxide, selenium hydroxide, sodium hydroxide, potassium hydroxide, calcium oxide, magnesium oxide, zinc oxide, iron oxide, selenium oxide, potassium oxide, magnesium chloride, and mixtures thereof;
a second compound selected from the group consisting of propionic acid, formic acid, acetic acid, citric acid, butyric acid, valeric acid, caproic acid, oxalic acid, lactic acid, malic acid, phosphoric acid, benzoic acid, carbonic acid, and mixtures thereof; and
microcrystalline cellulose.
US Pat. No. 10,791,741

PLANT GROWTH REGULATOR

JIANGSU HUIFENG BIO AGRIC...

1. A plant growth regulator composition, comprising active components A and B, wherein the active component A is thidiazuron, and the active component B is amino-oligosaccharin, wherein the activity of active components A and B combined are greater than the sum of the activity of active components A and B alone.
US Pat. No. 10,792,255

RECONSTITUTED APOLIPOPROTEIN B LIPOPARTICLE, A PREPARATION METHOD AND USES THEREOF

National Chiao Tung Unive...

1. A method for preparing a reconstituted apolipoprotein B lipoparticle, comprising steps of:a) dissolving apolipoprotein B in a first buffer containing 1 wt % to 15 wt % amphiphilic compound and 2M to 8M urea to form a first mixture;
b) dissolving lipid in a second buffer containing 1 wt % to 15 wt % amphiphilic compound and 2M to 8M urea to form a second mixture;
c) filtering the first mixture and the second mixture, respectively;
d) combining the first mixture and the second mixture to form a third mixture;
e) dialyzing the third mixture against a first folding buffer to reduce concentrations of the urea and the amphiphilic compound in the third mixture and obtain a first dialyzed mixture, wherein the concentration of the urea ranges from 0 to 2 M and the concentration of the amphiphilic compound ranges from 0 to 0.5 wt % in the first folding buffer;
f) dialyzing the first dialyzed mixture against a second folding buffer to reduce concentrations of the urea and the amphiphilic compound in the first dialyzed mixture and obtain a second dialyzed mixture, wherein the concentration of the urea ranges from 0 to less than or equal to 2 M and the concentration of the amphiphilic compound ranges from 0 to less than or equal to 0.5 wt % in the second folding buffer; and
g) repeating f) to stepwise reduce the concentrations of the urea and the amphiphilic compound,
wherein the lipid is at least one selected from the group consisting of phospholipid, cholesterol and triglyceride, and the amphiphilic compound is a non-ionic surfactant or bile acid.
US Pat. No. 10,796,610

IN-LINE PRODUCTION OF LINERLESS LABELS

MALLYA CONSULTING LLC, S...

1. A label laminate comprising:a filmic or a paper substrate, said substrate having a first surface and a second surface;
a pressure sensitive adhesive (PSA) layer, said PSA layer being tacky and having a first surface and a second surface, the first surface of the PSA being in contact with the second surface of the substrate;
a detack layer deposited on top of the second surface of the PSA layer, the detack layer comprising at least a plasticizer, the detack layer having a melting point above about 50° C., the detack layer upon melting and becoming compatible with the PSA layer does not substantially change the glass transition temperature of the PSA layer; and
the detack layer has a surface coverage of less than 100% of the second surface of the PSA layer.
US Pat. No. 10,791,744

PEST CONTROL FORMULATIONS AND METHODS OF MAKING AND USING SAME

0903608 B.C. Ltd., Vanco...

1. An emulsion consisting essentially of a pesticidal natural oil and a polar aromatic solvent,wherein the polar aromatic solvent is an aryl alcohol selected from the group consisting of 3,4-dimethylbenzyl alcohol, alpha-4-dimethylbenzyl alcohol, 2-phenyl-2-propanol, 1-phenylethanol, and combinations thereof, and
wherein the pesticidal natural oil is selected from the group consisting of neem oil, clove oil, cinnamon oil, thyme oil, garlic oil, wintergreen oil, lemongrass oil, lavender oil, lime oil, geranium oil, anise oil, and combinations thereof.
US Pat. No. 10,792,256

PHARMACEUTICAL COMPOSITION

MEXICHEM FLUOR S.A. DE C....

1. A pharmaceutical composition for a metered dose inhaler comprising:(i) a drug component consisting of at least one salmeterol compound selected from salmeterol and the pharmaceutically acceptable salts thereof either alone or together with at least one long acting muscarinic antagonist (LAMA) and/or at least one corticosteroid selected from mometasone, beclomethasone, fluticasone and the pharmaceutically acceptable salts and esters thereof; and
(ii) a propellant component comprising 1,1-difluoroethane (HFA-152a), wherein the composition contains greater than 0.5 ppm and less than 500 ppm of water based on the total weight of the pharmaceutical composition.
US Pat. No. 10,793,536

VORTIOXETINE PAMOIC ACID SALT AND CRYSTAL FORM THEREOF

SHANGHAI SYNERGY PHARMACE...

1. A compound, which is a vortioxetine pamoic acid salt, with a structural formula of (C18H22N2S)t.C23H16O6·nH2O, wherein r is 1 or 2, n=0˜10.
US Pat. No. 10,792,257

PHARMACEUTICAL COMPOSITIONS COMPRISING SAFINAMIDE

Zambon S.P.A., Bresso (M...

1. A plurality of particles, each including:a. a core comprising safinamide or a pharmaceutically acceptable salt thereof and a binder; and
b. a polymer composition which forms a coating on said core.
US Pat. No. 10,793,794

PROCESS AND SYSTEM FOR CONVERSION OF CRUDE OIL TO PETROCHEMICALS AND FUEL PRODUCTS INTEGRATING SOLVENT DEASPHALTING OF VACUUM RESIDUE

SAUDI ARABIAN OIL COMPANY...

1. An integrated system for producing petrochemicals and fuel products comprising:an atmospheric distillation unit (ADU) operable to receive and separate a feed, and discharge a first ADU fraction comprising naphtha, a second ADU fraction comprising at least a portion of middle distillates from the feed, and a third ADU fraction comprising atmospheric residue;
a vacuum distillation unit (VDU) operable to receive and separate the third ADU fraction, and discharge a first VDU fraction comprising vacuum gas oil and a second VDU fraction comprising vacuum residue;
a solvent deasphalting zone operable to receive and separate the second VDU fraction comprising vacuum residue into a deasphalted oil phase and an asphalt phase;
a distillate hydroproces sing (DHP) zone operable to receive and convert middle distillates from the second ADU fraction into a first DHP fraction and a second DHP fraction, wherein the first DHP fraction comprises naphtha and the second DHP fraction is used for diesel fuel production;
a gas oil hydroproces sing (GOHP) zone operable to receive and treat vacuum gas oil from the first VDU fraction and the deasphalted oil phase and produce a first GOHP fraction containing naphtha range components, and a second GOHP fraction containing heavy oil, which is hydrotreated gas oil or unconverted oil in the vacuum gas oil range;
a steam cracking zone comprising (a) a mixed feed steam cracking (MFSC) zone operable to receive and thermally crack naphtha from the first ADU fraction and a C6-C9 non-aromatics raffinate stream derived from an aromatics extraction zone, and (b) a gas oil steam cracking (GOSC) zone operable to receive and thermally crack the second GOHP fraction, wherein the steam cracking zone is operable to produce a mixed product stream containing mixed C1-C4 paraffins and olefins, a pyrolysis gas stream, and a pyrolysis oil stream;
a naphtha hydroproces sing zone operable to receive and treat the pyrolysis gas stream and produce a hydrotreated pyrolysis gas stream; and
the aromatics extraction zone operable to receive and separate the hydrotreated pyrolysis gas stream into one or more aromatic products streams, and the C6-C9 non-aromatics raffinate stream.
US Pat. No. 10,792,258

ANTISEPTIC, ANTISEBORRHEIC AND EXFOLIATING COMPOSITION TO REMOVE OR PREVENT ACNE

Excalibur Pharmaceuticals...

1. A hydrosoluble, topical pharmaceutical composition comprising from 0.001 to 10% by weight of diallyl disulfide modified oxide, from 1 to 12% by weight of glycolic acid, from 0.3 to 24% by weight of one or more surfactants, from 0.3 to 10% by weight of a moisturizing agent, from 0.2 to 10% by weight of an aromatizing agent, and from 40 to 70% by weight of an aqueous solvent.
US Pat. No. 10,792,259

COMPOSITIONS COMPRISING BETA-HYDROXYBUTYRIC ACID AND SALT, AND METHODS OF USING THE SAME

Savlnd, Inc., Urbana, IL...

1. A composition comprising ?-hydroxybutyric free acid and ?-hydroxybutyrate salt, wherein the free acid and salt stand in a mass:mass ratio from about 75 parts free acid:about 57.5 parts salt to about 38.5 parts free acid:about 90 parts salt, wherein the salt is a mixture of potassium and sodium salts.
US Pat. No. 10,793,539

PROCESS FOR THE PREPARATION OF TOCOLS AND SQUALENE

PRAJ INDUSTRIES LIMITED, ...

1. A process for preparation tocols and squalene comprising:(a) providing a fatty acid distillate comprising tocols and squalene, wherein the fatty acid distillation is obtained during the refining of palm oil and comprises up to 1% tocols by weight;
(b) subjecting said distillate to esterification with methanol at desired conditions forming an esterified stream;
(c) subjecting said esterified stream to a first molecular distillation at a temperature between 140° C. to 190° C. in a vacuum of between 0.010 mmHg to 0.40 mmHg at a feed flow rate between 25 kg/h to 35 kg/h and an agitation rate of 280 RPM, thereby forming a first distillate stream and a first residue stream;
(d) subjecting said first residue stream to a second molecular distillation at a temperature between 200° C. to 250° C. in a vacuum of between 0.01 mmHg to 0.20 mmHg at a feed flow rate between 10 kg/h to 20 kg/h and an agitation rate of 280 RPM, thereby forming a second distillate stream and a second residue stream;
(e) subjecting said second distillate stream to a final molecular distillation at a temperature between 140° C. to 180° C. in a vacuum of between 0.020 mmHg to 0.40 mmHg at a feed flow rate between 25 kg/h to 35 kg/h and an agitation rate of 280 RPM, thereby forming a final distillate stream and a final residue stream; and
(f) subjecting said final residue stream to chromatographic separation to get a highly enriched composition of tocols and squalene, wherein said chromatographic separation is achieved using silica gel as a stationary phase.
US Pat. No. 10,792,260

RETINOPATHY TREATMENT

CHS PHARMA, INC., Miami,...

1. A method of treating oxidative stress-induced degeneration of photoreceptor cells and retinal pigment epithelial cells in an eye of a mammalian subject with dry macular degeneration, the method comprising the step of administering an ophthalmically-acceptable pharmaceutical composition comprising a sulindac agent to the eye of the subject in an amount sufficient to reduce oxidative stress-induced degeneration of photoreceptor cells and retinal pigment epithelial cells in the eye of a mammalian subject, wherein the oxidative stress-induced degeneration of photoreceptor cells and retinal pigment epithelial cells in the eye of a mammalian subject is reduced after the step of administering the pharmaceutical composition.
US Pat. No. 10,793,797

INTEGRATED PROCESS AND UNIT OPERATION FOR CONDITIONING A SOOT-CONTAINING SYNGAS

PRAXAIR TECHNOLOGY, INC.,...

1. An integrated process for conditioning a soot-containing synthesis gas stream, comprising:(a) introducing a raw soot-containing synthesis gas having particulate matter and gaseous contaminants therein at a temperature of less than about 900° F. into a quenching device to reduce the temperature of said synthesis gas to a range of about 250-400° F., thereby forming a two-phase stream;
(b) routing the two-phase stream through a first scrubber device to substantially transfer majority of particulate matter from the gas phase to the liquid phase;
(c) directing said two-phase stream to a second scrubbing device wherein the two-phase stream is separated into a liquid-phase fluid contaminated with particulate matter and a gas-phase fluid having water-soluble contaminants at a lower section of the scrubbing device;
(d) cleaning and cooling the gas-phase fluid having water-soluble contaminants in an upper section of the second scrubbing device where the gas-phase fluid comes in direct contact with process water cooled to a temperature below 150° F. dispensed through a spray nozzle device thereby reducing the temperature of the gas phase fluid below the dew point temperature and removing water soluble impurities and remaining particulate matter therefrom;
(e) further routing the cooled and cleaned gas phase fluid of step (d) through a mist eliminating device disposed in the upper section of the second scrubbing device to remove substantially all of the remaining entrained water droplets, thereby producing a cooled and substantially soot-free synthesis gas stream.
US Pat. No. 10,792,261

EXTENDED, DELAYED AND IMMEDIATE RELEASE FORMULATION METHOD OF MANUFACTURING AND USE THEREOF

WELLESLEY PHARMACEUTICALS...

1. A method for manufacturing a pharmaceutical composition for reducing the frequency of urination, comprising:forming a core structure comprising immediate release particles comprising one or more first active ingredients and extended release particles comprising one or more second active ingredients, wherein the immediate release particles in the core structure are formulated for immediate release of the one or more first active ingredients after gastric emptying, and wherein the extended release particles are formulated for extended release of the one or more second active ingredients after gastric emptying;
coating the core structure with a delayed release coating to form a coated core structure;
coating the coated core structure with a one or more third active ingredients formulated to release the one or more third active ingredients immediately after administration,
wherein each of the one or more first, second and third active ingredients is an analgesic agent, and wherein the analgesic agents are the only active ingredients in the composition.
US Pat. No. 10,791,750

CONFECTIONARY RESEMBLING JEWELS

1. A confectionary comprising:a jewel-shaped candy having a candy body defining a shape resembling a jewel and having a color tint and flavor, said candy body having an outer surface defining a plurality of outer facets;
a plurality of dispersed shimmer facets formed at mutually converging angles within said candy body
a breath-enhancing substance added to said jewel-shaped candy; and
a package receiving and displaying said jewel-shaped candy,
said jewel-shaped candy formulated to include a Xylitol base ingredient, an odor-neutralizing ingredient, a fruit sugar, a saliva production enhancing ingredient, and a flavor ingredient.
US Pat. No. 10,792,262

STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES

SAOL INTERNATIONAL LIMITE...

1. A pharmaceutical composition, comprising:an active ingredient selected from 4-amino-3-(4-chlorophenyl)butanoic acid) (“baclofen”) and its pharmaceutically acceptable salts; and
poly(butylmethacrylate-co-(2-dimethylaminoethyl)methacrylate-co-methyl methacrylate) (“stabilizer”);
wherein a weight ratio of the stabilizer to the active ingredient is from 1.5:1 to 10:1 and wherein the active ingredient and stabilizer are present in a matrix.
US Pat. No. 10,795,081

METHOD FOR MEASURING AND DYNAMICALLY MODULATING CHARACTERISTICS OF SLOW LIGHT IN PHOTONIC-CRYSTAL COUPLED-CAVITY WAVEGUIDE

Qingdao University, Qing...

1. A method for measuring and dynamically modulating characteristics of slow light in a photonic-crystal coupled-cavity waveguide comprising:forming a photonic-crystal structure consisting of a series of microcavity components formed by,
arranging silicon dielectric rods in triangular lattice structure in the substrate of organic polymer polystyrene with an electro-optical effect, a light waveguide structure being along the X direction; and
regularly removing single silicon dielectric rods.
US Pat. No. 10,792,263

METHOD OF TREATING AN INDIVIDUAL HAVING A MICROBIAL INFECTION

Sun Yat-Sen University, ...

1. A method of treating an individual having a microbial infection, the method comprising:administering to the individual having a microbial infection an effective amount of a pharmaceutical formulation comprising glycine or a glycine derivative, and, optionally, one or more of serine and threonine, wherein the glycine or glycine derivative, and optionally, one or more of serine or threonine, wherein the glycine or glycine derivative is present, and the serine and threonine, respectively, when present, is present in an effective amount to elevate a bactericidal effect of a biological fluid comprising serum, plasma or blood against the microbial infection, and to kill a gram-negative bacterial pathogen or gram-positive bacterial pathogen within the biological fluid, and wherein the microbial infection is induced by the gram-negative bacterial pathogen or the gram-positive bacterial pathogen selected from Edwardsiella tarda, beta-hemolytic Streptococcus, Escherichia coli and Vibrio.
US Pat. No. 10,793,800

LUBRICANT COMPOSITIONS AND METHODS OF USE

Aero Accessories, LLC, G...

1. A lubricant composition consisting essentially by volume:30 to 50% of a graphite in alcohol solution, the graphite in alcohol solution comprising between 10 to 30% by volume of graphite placed in an alcohol solution;
0.1 to 5% surfactant; and
40 to 70% water.
US Pat. No. 10,792,008

PREPARATION METHOD OF RADIOACTIVE SOURCE

SHANGHAI NEUSOFT MEDICAL ...

1. A method of preparing a radioactive source, comprising:preparing a preset dose of a radiopharmaceutical, wherein the radiopharmaceutical is Fludeoxyglucose F 18, and a half-life of the radiopharmaceutical is shorter than 7 days; and
obtaining a solid radioactive source having a predetermined shape by mixing and moulding the radiopharmaceutical with a preset solution and a moulding material, the solid radioactive source is for diagnosing a Positron Emission Tomography (PET) device, wherein preset solution comprises water or sodium chloride solution
wherein mixing and moulding the radiopharmaceutical with the preset solution and the moulding material comprises:
mixing the radiopharmaceutical with the preset solution to obtain a second mixture;
preparing a water-absorbing material as the moulding material, wherein the water-absorbing material comprises a hydrogel, and the hydrogel and the second mixture are mixed according to a ratio range of 1:150 to 2000;
and to obtain the solid radioactive source.
US Pat. No. 10,792,264

TREATMENT AND PREVENTION OF MUSCLE LOSS USING L-ORNITHINE IN COMBINATION WITH AT LEAST ONE OF PHENYLACETATE AND PHENYLBUTYRATE

Ocera Therapeutics, Inc.,...

1. A method of treating a condition of muscle loss, comprising administering ornithine in combination with at least one of phenylacetate and phenylbutyrate to a subject suffering from a condition of muscle loss, and thereby relieving the muscle loss condition.
US Pat. No. 10,792,265

METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES

Yale University, New Hav...

1. A method of treating or ameliorating a fibrotic lung disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of at least one thyroid hormone using an administration route selected from the group consisting of nasal, inhalational, intratracheal, intrapulmonary, intrabronchial, and inhalation.
US Pat. No. 10,793,802

MIXED PHOSPHORUS ESTERS FOR LUBRICANT APPLICATIONS

The Lubrizol Corporation,...

1. A lubricant composition comprising an oil of lubricating viscosity and a phosphite ester composition (A), other than a zinc salt, which comprises the reaction product of(a) a monomeric phosphorous acid or an ester thereof with
(b) at least two alkylene diols:
a first alkylene diol (i) having two hydroxy groups in a 1,4 or 1,5 or 1,6 relationship;
a second alkylene diol (ii) being an alkyl-substituted 1,3-propylene diol with one or more of the alkyl substituents thereof being on one or more of the carbon atoms of the propylene unit, the total number of carbon atoms in the alkyl-substituted 1,3-propylene diol being about 5 to about 12;
wherein the relative molar amounts of monomeric phosphorous acid or ester thereof (a) and the total of the alkylene diols (b) are in a ratio of about 0.9:1.1 to about 1.1:0.9; and
wherein the relative molar amounts of the first alkylene diol (i) and the alkyl-substituted 1,3-propylene diol (ii) are in a ratio of about 30:70 to about 65:35.
US Pat. No. 10,791,754

HONEY PRODUCT HAVING A LOW WATER CONTENT

IAF SCIENCE HOLDINGS LTD....

1. A solid honey product consisting of honey and optionally a flavor and/or an upper respiratory care ingredient, wherein the solid honey product has a moisture content equal to or lower than 0.1% (w/w).
US Pat. No. 10,792,266

FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME

Epitracker, Inc., San Di...

1. A method of treatment or prophylaxis of a condition selected from the group consisting of metabolic syndrome, cardiovascular disease, diabetes, type 2 diabetes, anemia, dyslipidemia, hypertension, inflammation, a chronic inflammatory disease, rheumatoid arthritis, insulin resistance, a fibrotic disease, prediabetes, fatty liver disease, steatohepatitis, iron overload, and nonalcoholic steatohepatitis, comprising:administering to a patient in need thereof a pharmaceutical composition comprising an effective amount of 2-methylpentadecanoic acid, or pharmaceutically acceptable salt thereof.
US Pat. No. 10,793,803

GASOLINE ENGINE LUBRICANT OIL COMPOSITION AND MANUFACTURING METHOD THEREFOR

IDEMITSU KOSAN CO., LTD.,...

1. A method, comprising:lubricating a gasoline engine with a lubricating oil composition, wherein the lubricating oil composition comprises:
a base oil;
a molybdenum dithiocarbamate;
a calcium detergent comprising a calcium salicylate;
a magnesium detergent comprising a magnesium sulfonate;
a boron-free succinimide; and
a boron-containing succinimide,
wherein:
a content of the base oil in the lubricating oil composition is 70 mass % or more relative to the whole amount of the lubricating oil composition;
a content of the molybdenum dithiocarbamate in the lubricating oil composition as converted into a molybdenum atom is from 400 to 1,000 ppm by mass on a basis of a whole amount of the lubricating oil composition;
only the calcium salicylate is present as the calcium detergent and a content of the calcium detergent in the lubricating oil composition as converted into a calcium atom is from 1,000 to 2,000 ppm by mass a basis of the whole amount of the lubricating oil composition,
only the magnesium sulfonate is present as the magnesium detergent and a content of the magnesium detergent in the lubricating oil composition as converted into a magnesium atom is from 200 to 1,000 ppm by mass on a basis of the whole amount of the lubricating oil composition;
a content of the boron-free succinimide in the lubricating oil composition as converted into a nitrogen atom is 690 ppm by mass or less on a basis of the whole amount of the lubricating oil composition;
a content of the boron-containing succinimide in the lubricating oil composition as converted into a boron atom is from 220 to 600 ppm by mass on a basis of the whole amount of the lubricating oil composition;
a mass ratio of the molybdenum atom (Mo) to a magnesium atom (Mg) of the magnesium detergent [Mo/Mg] in the lubricating oil composition is 0.4 or more; and
wherein a time until the friction coefficient becomes less than 0.10 of the lubricating oil composition is 200 seconds or shorter, as measured with an HFRR tester equipped with a ball comprised of an AISI 52100 material and a disc comprised of an AISI 52100 material at an amplitude of 1.0 mm, a frequency of 50 Hz, a load of 5 g, and at temperature of 80° C.
US Pat. No. 10,792,267

METHODS OF TREATING MIXED DYSLIPIDEMIA

Amarin Pharmaceuticals Ir...

1. A method of treating or preventing a cardiovascular disease in a subject on statin therapy having type 2 diabetes, the method comprising administering to the subject a pharmaceutical composition comprising about 4 g of eicosapentaenoic acid ethyl ester per day, wherein the cardiovascular disease is myocardial infarction, stroke, or both.
US Pat. No. 10,791,756

RECONSTITUTED TOBACCO SHEETS AND RELATED METHODS

Philip Morris Products S....

1. A method of making a reconstituted tobacco sheet, comprising:providing tobacco stems or tobacco stalks or a mixture thereof;
conditioning the tobacco stems or tobacco stalks such that their moisture content is increased to from about 40% Oven Volatiles (OV) to about 60% Oven Volatiles (OV);
processing the conditioned tobacco stems or tobacco stalks in a twin screw extruder to so as to obtain a pulp suspension having a Schopper-Riegler index of at least about 30 degrees and comprising tobacco stem or tobacco stalk refined fibres having an average length of at least about 200 micrometres;
combining the pulp suspension with tobacco cast leaf material to obtain a slurry; and
forming a sheet from the slurry.
US Pat. No. 10,793,805

AQUEOUS LUBRICATING COMPOSITION

SOPURA S.A., Courcelles ...

1. A lubricating composition, comprising:from 0.1% to 10% by weight of a first organic acid being fatty acid containing from 8 carbon atoms to 12 carbon atoms;
from 1% to 10% by weight of a fatty amine containing from 12 carbon atoms to 22 carbon atoms, wherein the fatty amine is a polyamine;
from 0.1% to 5% by weight of an acidity corrector;
from 0.1% to 10% by weight of a dispersant;
from 0.1% to 10% by weight of a second organic acid;
from 0.1% to 10% by weight of an organic solvent; and
from 50% to 98.8% by weight of water.
US Pat. No. 10,794,830

DETECTION OF ORGANIC FREE RADICALS AND REACTIVE OXYGEN SUBSTANCES USING CHEMICALLY-STIMULATED LUMINESCENCE FROM STRUCTURED COMPOUND SEMICONDUCTORS

UNIVERSITY OF KENTUCKY RE...

1. A method of monitoring for presence of an oxidizing chemical species in an environment, comprising:exposing a structured compound semiconductor material to said oxidizing chemical species in said environment; and
detecting electromagnetic radiation emitted by said structured compound semiconductor material upon exposure to said oxidizing chemical species,
wherein said structured compound semiconductor material is produced from a phytate scaffold material and a metal dopant, said structured compound semiconductor material emitting electromagnetic radiation upon exposure to the oxidizing chemical species.
US Pat. No. 10,792,269

GLYCERYL 3-HYDROXYBUTYRATES FOR MIGRAINE SYMPTOM MANAGEMENT

NeuroEnergy Ventures, Inc...

1. A method of use of a glyceryl (3-hydroxybutyrate) ester compound in the management of migraine symptomology comprising:orally administering an amount of said compound, which, upon being hydrolyzed, gives rise to glycerol and 3-hydroxybutylate moieties,
(a) to a subject presenting with at least one migraine symptom, wherein said amount is sufficient to eliminate, control, limit, or reduce said at least one symptom or
(b) to a subject so as to prevent the onset of at least one of said symptoms from a previously established pattern of migraine symptom onset, said amount of said compound which is administered is sufficient to raise the subject's ketone body blood plasma levels, as measured by the subject's combined blood plasma levels of 3-hydroxybutyrate and acetoacetate, to a range having a lower and upper limit selected from 6 mM, 6.5 mM, 7 mM and about 7.5 mM within the first 24 hours of administration of said glyceryl (3-hydroxybutyrate) ester compound, provided said upper limit of the range is larger than the lower limit of the range.
US Pat. No. 10,793,806

CONVEYOR LUBRICANTS INCLUDING EMULSIONS AND METHODS EMPLOYING THEM

Ecolab USA Inc., St. Pau...

1. A method for lubricating the passage of a container along a conveyor, comprising:applying a lubricating emulsion to at least a portion of a container-contacting surface of the conveyor or to at least a portion of a conveyor-contacting surface of the container, the lubricating emulsion comprising:
(a) a water insoluble oil with viscosity greater than about 300 centipoise;
(b) about 0 to about 0.35 wt-% emulsifier; and
(c) about 99.3 to about 99.99 wt-% water, inclusive of any hydrophilic diluents;
wherein the lubricating emulsion is applied for a period of time and not applied for a period of time and the ratio of not applied:applied time is between 2:1 and 32:1 and the not applied time is from about 30 seconds to 12 minutes.
US Pat. No. 10,797,136

MULTILAYER GRAPHENE QUANTUM CARBON-BASED SEMICONDUCTOR MATERIAL PREPARED FROM PI FILM, AND PREPARATION METHOD THEREFOR

SHENZHEN DANBOND TECHNOLO...

1. A method for preparing a multilayer graphene quantum carbon-based two-dimensional semiconductor material, comprising steps ofstep S1. taking a polyimide film as a raw material, and performing polymer sintering at a first temperature, to remove H, O and N atoms to form a microcrystalline carbon precursor, wherein the PI film is obtained by producing polyimide by mutually hybridizing an aromatic diamine with an aromatic polyanhydride and introducing a methyl group, followed by cyclodehydration, polycondensation, and imidization; and the polyimide film is carbonized by the polymer sintering, to form an aromatic heterocyclic compound in a microcrystalline state with a large continuous region, and finally form a microcrystalline carbon precursor having an artificial heterogeneous graphite structure; and
step S2. graphitizing the carbon precursor at a second temperature, to form a multilayer graphene quantum carbon-based two-dimensional semiconductor material, wherein after the graphitization, a bendable flexible graphene structure is formed,
wherein in at least the step S2, a nano metal material is doped to form quantum dots in the multilayer graphene.
US Pat. No. 10,792,270

METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT AT RISK FOR CARDIOVASCULAR DISEASE

Amarin Pharmaceuticals Ir...

1. A method of reducing risk of coronary revascularization in a subject with established cardiovascular disease, the method comprising administering to said subject about 4 g of ethyl icosapentate per day for a period effective to reduce risk of coronary revascularization in the subject.
US Pat. No. 10,793,550

4-PIPERIDIN-N-(PYRIMIDIN-4-YL)CHROMAN-7-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS

GENENTECH, INC., South S...

1. A compound selected from the group consisting of:(S)-6-fluoro-4-((2S,4R)-2-(pyridin-2-yl)-4-(trifluoromethyl)piperidin-1-yl)-N-(pyrimidin-4-yl)chroman-7-sulfonamide;
(S)-6-fluoro-4-((2S,4S)-2-(4-fluorophenyl)-4-hydroxy-4-(trifluoromethyl)piperidin-1-yl)-N-(pyrimidin-4-yl)chroman-7-sulfonamide;
(S)-4-((2S,4R)-4-(difluoromethoxy)-2-(4-fluorophenyl)piperidin-1-yl)-6-fluoro-N-(pyrimidin-4-yl)chroman-7-sulfonamide; and
(S)-6-fluoro-4-((2R,4R)-2-methyl-4-(3-(trifluoromethyl)phenyl)piperidin-1-yl)-N-(pyrimidin-4-yl)chroman-7-sulfonamide;
or a pharmaceutically acceptable thereof.
US Pat. No. 10,793,807

ORGANOLEPTIC COMPOUNDS

1. A fragrance composition comprising an olfactory acceptable amount of a compound, 2,2,4-trimethylpentane-1,3-diyl diacetate.
US Pat. No. 10,792,271

TOPICAL FORMULATIONS OF CHLOROPROCAINE AND METHODS OF USING SAME

Sintetica S.A., Mendrisi...

1. A method of inducing local analgesia or anesthesia in an eye of a mammalian subject comprising topically administering to said eye a topical gel formulation comprising:a) a therapeutically effective amount of a single anesthetic consisting of chloroprocaine HCl for inducing said local analgesia or anesthesia;
b) one or more thickening agents;
c) hydrochloric acid in an amount sufficient to impart a pH of from 2.8 to 3.6 to the formulation; and
d) water;
wherein hydrochloric acid is the sole pH adjusting agent in the formulation.
US Pat. No. 10,793,808

POTASSIUM SOAPS THAT CAN BE THICKENED WITH CHLORIDE SALTS

Vanguard Soap LLC, Memph...

1. A soap composition consisting essentially of:a. one or more fatty acids with a carbon chain length of C4 to C22;
b. one or more natural oils selected from the group consisting of coconut oil, olive oil, sunflower oil, safflower oil, wherein the one or more natural oils is combined with the one or more fatty acids;
c. a lye selected from the group of potassium hydroxide, sodium hydroxide, or combinations thereof, wherein the one or more fatty acids and one or more natural oils are saponified with the lye;
d. and a chloride salt at a weight of 7% or less selected from the group consisting of dry sodium chloride, aqueous sodium chloride solution, dry potassium chloride, aqueous potassium chloride solution, and combinations thereof, wherein the chloride salt is added to the saponified fatty acids after a neutralizing process and does not affect clarity or color, or cause the soap composition to separate or become less viscous.
US Pat. No. 10,792,785

CHEMICAL-MECHANICAL PROCESSING SLURRY AND METHODS FOR PROCESSING A NICKEL SUBSTRATE SURFACE

Cabot Microelectronics Co...

1. A method of treating a nickel-phosphorus surface at a low pH, the method comprising:providing a substrate having a nickel-phosphorus surface,
providing a slurry having a pH below 3, the slurry comprising:
liquid carrier,
cationic silica abrasive particles dispersed in the liquid carrier, the cationic silica abrasive particles containing cationic compound that is a nitrogen-containing compound or a phosphorus-containing compound, wherein the silica abrasive particles exhibit a zeta potential in a range from 5 to 60 millivolts in the slurry at the slurry pH, and
oxidizing agent, and
contacting the substrate surface with the slurry to remove nickel-phosphorus material from the surface.
US Pat. No. 10,792,018

METHOD FOR OBTAINING FETAL CELLS AND FETAL CELLULAR COMPONENTS

Preprogen LLC, Monroe, N...

1. A method of obtaining fetal stem cells, comprisingplacing an absorbent medium in an interlabial space external to a vaginal opening of a pregnant female with an intact amniotic sac,
collecting vaginal fluid comprising cells in the absorbent medium while the absorbent medium is in the interlabial space;
removing the absorbent medium;
extracting the vaginal fluid from the absorbent medium; and
isolating fetal stem cells from the vaginal fluid extracted from the absorbent medium, wherein isolating the fetal stem cells comprises separating the fetal stem cells from maternal cells in the vaginal fluid using an antibody that specifically binds to TRA-1-81, thereby obtaining the fetal stem cells.
US Pat. No. 10,793,554

SOLID FORMS OF 4-(2-FLUORO-4-(1-METHYL-1H-BENZO[D]IMIDAZOL-5-YL)BENZOYL)PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE

Forma Therapeutics, Inc.,...

1. A solid form of the free base of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone designated the Form B solid form that exhibits a X-ray powder diffraction pattern (XRPD) (a) having characteristic peaks expressed in degrees 2-theta (±0.2 degrees 2-theta) at 9.6, 10.1, 15.4, 19.6, and 22.3 and (b) characterized by the absence of a characteristic peak expressed in degrees 2-theta (±0.2 degrees 2-theta) at 24.2.
US Pat. No. 10,795,349

METHOD AND DEVICE FOR TESTING SOFTWARE OF AN ELECTRONIC CONTROL UNIT OF A VEHICLE

IAV GMBH INGENIEURGESELLS...

1. A method for testing software of an electronic control unit of a vehicle, the software comprising functions for processing input quantities that serve to form output quantities of the electronic control unit, the method comprising:in a first step, executing a driving cycle with the vehicle on a testing device, whereby the vehicle is not moving with respect to the surroundings, the input quantities and output quantities of the electronic control unit being recorded in the first step;
in an additional step, repeating the driving cycle in accordance with the first step without once again executing the driving cycle with the vehicle on the testing device so that additional output quantities are made available, the driving cycle being repeated in the additional step in that the software or the electronic control unit is excited or stimulated with the input quantities that had been recorded in accordance with the first step, wherein at least one input quantity that serves to excite or stimulate the software and that had been recorded in the first step is changed in the additional step in such a way that a movement of the vehicle with respect to the surroundings is simulated;
comparing the output quantities that had been recorded in the first step to the additional output quantities that are available in accordance with the additional step;
ascertaining that the software comprises a function that recognizes whether or not a driving cycle is being executed with the vehicle on the testing device, based on there being a deviation between at least one output quantity that had been recorded in the first step and the corresponding output quantity provided in accordance with the additional step; and, based thereon,
excluding at least one of the functions of the electronic control unit from being further developed or processed during a subsequent development step.
US Pat. No. 10,792,277

METHODS OF TREATMENT OF FIBROSIS AND CANCERS

GENFIT, Loos (FR)

1. A method of treating a fibrotic disease in a person in need thereof, wherein the fibrotic disease is not liver fibrosis, said method comprising administering to the person an effective amount of a tyrosine kinase inhibitor, wherein the tyrosine kinase inhibitor is 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,792,278

METHODS OF TREATING FABRY PATIENTS HAVING RENAL IMPAIRMENT

Amicus Therapeutics, Inc....

1. A method of stabilizing renal function in a patient diagnosed with Fabry disease and having severe renal impairment with an eGFR less than 30 mL/min/1.73 m2, the method comprising:administering to the patient about 100 mg to about 150 mg free base equivalent (FBE) of migalastat at a frequency of once every other day,
wherein administration of a single dose of the migalastat to subjects provides an increase in plasma migalastat AUC0-? of about 4.5-fold compared to a healthy control subject, and
wherein the administration of the migalastat is effective to stabilize renal function in the patient and wherein the patient has a HEK assay amenable mutation in ?-galactosidase A.
US Pat. No. 10,792,279

METHODS OF TREATING FABRY PATIENTS HAVING RENAL IMPAIRMENT

Amicus Therapeutics, Inc....

1. A method of stabilizing renal function in enzyme replacement therapy (ERT)-experienced patients diagnosed with Fabry disease and having mild renal impairment with an eGFR of 60 to 90 mL/min/1.73 m2, the method comprising:administering, to a group of Fabry disease patients having mild renal impairment and a HEK assay amenable ?-galactosidase A mutation, about 100 mg to about 150 mg free base equivalent (FBE) of migalastat at a frequency of once every other day;
wherein the administration is effective to (i) reduce mean globotriaosylceramide (GL-3) accumulated in an organ of the patients, (ii) reduce mean plasma globotriaosylsphingosine (lyso-Gb3) in the patients, (iii) increase mean white blood cell (WBC) ?-galactosidase A activity in the patients, (iv) reduce mean left ventricular mass index (LVMi) in the patients, and (v) stabilize mean renal function in the patients; and
wherein administration of a single dose of the migalastat to the patients is effective to provide (i) a mean plasma migalastat increase in AUC0??of about 1.2-fold compared to healthy control subjects, and (ii) no increase in mean plasma migalastat Cmax compared to healthy control subjects.
US Pat. No. 10,792,281

LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF INFLAMMATION MEDIATED CONDITIONS

IRR, Inc., Santa Barbara...

1. A method of treating an NF?B-mediated mediated condition comprising administering to a patient an effective amount of a combination of levocetirizine and montelukast.
US Pat. No. 10,792,282

PROTEIN KINASE C INHIBITORS AND USES THEREOF

Rigel Pharmaceuticals, In...

1. A method of treating a disease or disorder, comprisingadministering to a patient in need thereof a pharmaceutically effective amount of a compound selected from the group consisting of:
Compound 77: 1-(2-(2-hydroxyethoxy)-5-(4-((7R,8aS)-octahydro-5,5-dimethylindolizin-7-ylamino)-5-fluoropyrimidin-2-ylamino)-4-fluorophenyl)-4-methyl-1H-tetrazol-5(4H)-one;
Compound 78: 4-((7R,8aS)-octahydro-5,5-dimethylindolizin-7-ylamino)-2-(4-(2-hydroxyethoxy)-2-fluoro-5-(4,5-dihydro-4-methyl-5-oxotetrazol-1-yl)phenylamino)pyrimidine-5-carbonitrile;
Compound 79: 4-((7R,8aS)-octahydro-5,5-dimethylindolizin-7-ylamino)-2-(4-((S)-2-hydroxypropoxy)-2-fluoro-5-(4,5-dihydro-4-methyl-5-oxotetrazol-1-yl)phenylamino)pyrimidine-5-carbonitrile;
Compound 80: 4-((7R,8aS)-octahydro-5,5-dimethylindolizin-7-ylamino)-2-(4-(2-hydroxy-2-methylpropoxy)-2-fluoro-5-(4,5-dihydro-4-methyl-5-oxotetrazol-1-yl)phenylamino)pyrimidine-5-carbonitrile;
Compound 81: 1-(2-((S)-2-hydroxypropoxy)-5-(4-((7R,8aS)-octahydro-5,5-dimethylindolizin-7-ylamino)-5-fluoropyrimidin-2-ylamino)-4-fluorophenyl)-4-methyl-1H-tetrazol-5(4H)-one;
Compound 82: 1-(5-(4-((7R,8aS)-5,5-dimethyloctahydroindolizin-7-ylamino)-5-fluoropyrimidin-2-ylamino)-4-fluoro-2-((R)-2-hydroxypropoxy)phenyl)-4-methyl-1H-tetrazol-5(4H)-one;
Compound 83: 4-((7R,8aS)-octahydro-5,5-dimethylindolizin-7-ylamino)-2-(4-(1-hydroxy-2-methylpropan-2-yloxy)-3-(4,5-dihydro-4-methyl-5-oxotetrazol-1-yl)phenylamino)pyrimidine-5-carbonitrile;
Compound 84: 4-((7R,8aS)-5,5-dimethyloctahydroindolizin-7-ylamino)-2-(2-fluoro-4-(1-hydroxy-2-methylpropan-2-yloxy)-5-(4-methyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)phenylamino)pyrimidine-5-carbonitrile;
Compound 85: 1-(5-(4-((7R,8aS)-5,5-dimethyloctahydroindolizin-7-ylamino)-5-fluoropyrimidin-2-ylamino)-4-fluoro-2-(1-hydroxy-2-methylpropan-2-yloxy)phenyl)-4-methyl-1H-tetrazol-5(4H)-one;
Compound 86: 1-(5-(4-((7R,8aS)-5,5-dimethyloctahydroindolizin-7-ylamino)-5-fluoropyrimidin-2-ylamino)-2-(1-hydroxy-2-methylpropan-2-yloxy)phenyl)-4-methyl-1H-tetrazol-5(4H)-one;
Compound 87: 1-(5-(4-((7R,8aS)-5,5-dimethyloctahydroindolizin-7-ylamino)-5-fluoropyrimidin-2-ylamino)-4-fluoro-2-(2-hydroxy-2-methylpropoxy)phenyl)-4-methyl-1H-tetrazol-5(4H)-one; and
Compound 90: 4-((7R,8aS)-octahydro-5,5-dimethylindolizin-7-ylamino)-2-(4-((R)-2-hydroxypropoxy)-2-fluoro-5-(4,5-dihydro-4-methyl-5-oxotetrazol-1-yl)phenylamino)pyrimindine-5-carbonitrile,
wherein the administering the pharmaceutically effective amount is effective for treating a disease or disorder selected from the group consisting of an inflammatory disease, an autoimmune disease, and an ocular disease or disorder involving inflammatory and/or neovascular events.
US Pat. No. 10,793,819

LIQUID INJECTION METHOD

KANEKA CORPORATION, Osak...

1. A method for culturing adherent cells, the method comprising:sucking a medium out of a culture vessel;
tilting the culture vessel around a horizontal axis at a tilt angle (X°) of greater than 0°to 50° or less, wherein adherent cells are adhered to the culture vessel;
injecting a fresh medium into the culture vessel at a predetermined linear velocity (Y mm/s) via a wall surface of the culture vessel tilted at the tilt angle (X°);
culturing the adherent cells; and
washing an interior of the culture vessel by injecting a washing solution into the culture vessel and sucking the washing solution out of the culture vessel, wherein the tilt angle (X°) and the linear velocity (Y mm/s) satisfy the following:
Y?5.075X+123  (formula 1).
US Pat. No. 10,793,307

FILL-FINISH PROCESS FOR PEPTIDE SOLUTIONS

3-D Matrix, Ltd., Tokyo ...

1. A method comprising:(a) a first deaerating step wherein an aqueous liquid composition of self-assembling peptides having an amino acid sequence of RADARADARADARADA (SEQ ID NO: 1)(“RADA16 peptides”) present at a concentration of at least 0.5 weight % is deaerated by lowering the pressure at a rate of less than about 0.01 MPa/min,
(b) a sterilizing step wherein the aqueous liquid composition is passed through a sterilizing filter producing an aqueous liquid filtrate, and wherein the sterilizing step is performed at a pressure of about 0.5 MPa; and
(c) a second deaerating step, wherein the aqueous liquid filtrate is deaerated by vibration and lowering the pressure.
US Pat. No. 10,792,284

SYNERGISTIC CANCER TREATMENT

Memorial Sloan Kettering ...

1. A method for treating a subject that (a) suffers from a KRAS mutant lung or pancreatic cancer, and (b) has received or is receiving a small molecule MEK inhibitor comprising:administering to the subject a therapeutically effective amount of a FGFR1 inhibitor, wherein the therapeutically effective amount of the FGFR1 inhibitor is sufficient to significantly reduce lung or pancreatic tumor volume compared to a control subject that is suffering from the KRAS mutant lung or pancreatic cancer and has been treated with the small molecule MEK inhibitor, and wherein the FGFR1 inhibitor is or comprises an antibody agent or a small molecule.
US Pat. No. 10,792,285

STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING PEMETREXED OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Chong Kun Dang Pharmaceut...

1. A composition comprising pemetrexed or a pharmaceutically acceptable salt thereof as an active ingredient and 0.50 mg/mL to 1.25 mg/mL of monothioglycerol as an antioxidant.
US Pat. No. 10,793,565

HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS

Incyte Corporation, Wilm...

1. A compound which is N-(3?-(8-chloro-6-((2-hydroxyethylamino)methyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-2,2?-dimethylbiphenyl-3-yl)-5-((2-hydroxyethylamino)methyl)picolinamide, or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,792,286

TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA

Neurocrine Biosciences, I...

1. A method of treating Congenital Adrenal Hyperplasia (CAH), said method comprising administering to a subject in need thereof an effective amount of a CRF1 receptor antagonist, wherein the CRF1 receptor antagonist is 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propyn-1-yl)-2-thiazolamine (SSR-125543), or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,793,823

MICROBIOLOGICAL GROWTH MEDIA AND METHODS OF USING THE SAME

Rapid Micro Biosystems, I...

1. A composition comprising casein digest, soybean digest, animal tissue digest, yeast extract, dextrose, a phosphate buffer, hemin, and L-cystine, wherein said composition does not comprise tris(hydroxymethyl)aminomethane, wherein, at 22° C., said composition is solid, and, excluding said phosphate buffer from the total mass of said composition, said composition comprises between about 1 g/kg and about 500 g/kg of casein digest; between about 0.5 g/kg and about 300 g/kg of soybean digest; between about 1 g/kg and about 500 g/kg of animal tissue digest; between about 1 g/kg and about 500 g/kg of yeast extract; between about 1 g/kg and about 500 g/kg of dextrose; and between about 8 g/kg and about 40 g/kg of L-cystine.
US Pat. No. 10,792,287

METHODS FOR TREATING MITOCHONDRIAL DISEASES

The Regents of the Univer...

1. A method for attenuating the progression of a mitochondrial disease that leads to vision loss or blindness in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a drug selected from the group consisting of zolpidem, a pharmaceutically acceptable salt thereof, and an analog thereof, wherein inhibition of Aif1, Tlr2, B2m, Cc15, or Cxc110 inflammatory gene expression is detected after administration of the drug.
US Pat. No. 10,793,824

SALT FORMULATIONS FOR THE FERMENTATION OF MARINE MICROORGANISMS

1. A salt formulation for use in fermenting a marine microorganism, the formulation comprising:(a) NaCl in the salt formulation at a mass percent between 92% and 76%;
(c) KCl in the salt formulation at a mass percent between 5% and 1.50%;
(d) CaCl2?H2O in the salt formulation at a mass percent between 3% and 1%;
(e) SrCl2 in the salt formulation at a mass percent between 0.10% and 0.025%;
(f) H3BO3?7H2O in the salt formulation at a mass percent between 0.20% and 0.04%; and
(g) NaF in the salt formulation at a mass percent between 0.05% and 0.005%.
US Pat. No. 10,792,288

PRESERVATIVE FREE BRIMONIDINE AND TIMOLOL SOLUTIONS

ALLERGAN, INC., Irvine, ...

1. A preservative free brimonidine and timolol composition for lowering intraocular pressure in a human patient comprising the following formulation: about 0.2% w/v brimonidine tartrate; about 0.68% w/v timolol maleate; about 2.15% w/v sodium phosphate dibasic heptahydrate; about 0.43% w/v sodium phosphate monobasic heptahydrate and water wherein the preservative free brimonidine and timolol composition dosed twice a day lowers intraocular pressure to a greater degree as compared to a second composition dosed twice a day comprising about 0.2% w/v brimonidine tartrate; about 0.68% w/v timolol maleate; about 0.005% benzalkonium chloride; about 2.15% w/v sodium phosphate dibasic heptahydrate; about 0.43% w/v sodium phosphate monobasic heptahydrate and water.
US Pat. No. 10,793,825

MODIFIED GRAM POSITIVE BACTERIA AND USES THEREOF

INTREXON ACTOBIOTICS NV, ...

1. A composition comprising a lactic acid bacterium (LAB) or a Bifidobacterium, wherein the LAB or the Bifidobacterium lacks PtcC activity, wherein the LAB or the Bifidobacterium contains a functional heterologous trehalose-6-phosphate phosphatase gene, wherein the LAB or the Bifidobacterium further (a) constitutively overexpresses a gene encoding a trehalose transporter, or (b) lacks trehalose 6-phosphate phosphorylase (TrePP) activity, and wherein the composition is a food additive, a probiotic composition, or a starter culture.
US Pat. No. 10,792,289

USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS

Horizon Orphan LLC, Lake...

1. A method for treating a pulmonary infection, wherein the pulmonary infection comprises one or more Mycobacterium, the method comprising:administering via inhalation 240 mg of levofloxacin twice daily for 28 days to the human having cystic fibrosis to treat the Mycobacterium pulmonary infection;
wherein the levofloxacin is in an aerosol of a solution comprising levofloxacin at a concentration from about 90 mg/ml to about 110 mg/ml, a magnesium cation at a concentration from about 175 mM to about 225 mM, wherein the solution has a pH from about 5 to about 7, and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg.
US Pat. No. 10,793,826

GENETICALLY MODIFIED MICROORGANISMS HAVING IMPROVED TOLERANCE TOWARDS L-SERINE

CysBio Aps, Kgs. Lyngby ...

1. An Escherichia coli bacterium, which has been modified to inactivate at least one gene selected from sdaA, sdaB, tdcG or glyA by partial or entire deletion of the gene sequence, by shifting of the reading frame of the gene, by the introduction of a missense/nonsense mutation, or by the modification of the promoter or ribosome-binding site operably linked to the gene; wherein said Escherichia coli bacterium expresses an aspartate kinase I/homoserine dehydrogenase I (ThrA) mutant comprising an amino acid substitution at a position selected from the group consisting of Y356, S357 and S359 in the amino acid sequence of SEQ ID NO: 11.
US Pat. No. 10,792,290

PHARMACEUTICAL COMPOSITIONS CONTAINING TESTOSTERONE AND AN AROMATASE INHIBITOR

SUNNYBROOK PHARM, LLC, D...

1. A method of reducing estradiol levels comprising administering to a patient in need of testosterone therapy at least one implant comprising a mixture of an amount of testosterone or an ester thereof and an amount of aromatase inhibitor in a weight ratio of testosterone or an ester thereof to aromatase inhibitor of 5:1 to 30:1, wherein the mixture forms a single implant with continuous delivery and zero order release of the testosterone or ester thereof and the aromatase inhibitor for a period of at least 30 days.
US Pat. No. 10,793,827

CELL CULTURE MEDIUM COMPRISING SMALL PEPTIDES

Life Technologies Corpora...

1. A cell culture supplement comprising an alanine-cysteine dimer and alanine-tyrosine, wherein the cell culture supplement increases the titer of a recombinant protein produced in the cell, and wherein said cell is a mammalian cell, wherein the cell culture supplement is a dry powder, wherein the mammalian cell is genetically engineered.
US Pat. No. 10,792,291

APPLICATIONS FOR LEVONORGESTREL IN PREPARING ANTI-OVARIAN CANCER PRODUCTS

SHANGHAI JIAO TONG UNIVER...

1. A method for treating ovarian cancer comprising administering an effective amount of levonorgestrel to a subject in need thereof.
US Pat. No. 10,793,828

PROTEIN ENRICHED MICROVESICLES AND METHODS OF MAKING AND USING THE SAME

Takara Bio USA, Inc., Mo...

1. A micro-vesicle comprising:a membrane-associated chimeric protein comprising a first dimerization domain; and
a target chimeric protein that is not membrane-associated comprising a second dimerization domain,
wherein the first and second dimerization domains are specifically bound to each other in a dimerized complex or the first and second dimerization domains are bound to each other by a single dimerization mediator.
US Pat. No. 10,793,829

TRANSGENIC MAMMALS AND METHODS OF USE THEREOF

TRIANNI, INC., San Franc...

1. A transgenic mouse with a genome in which a mouse endogenous immunoglobulin variable gene locus has been deleted and replaced with an engineered partly bovine immunoglobulin locus comprising bovine immunoglobulin variable gene VH, DH and JH and/or bovine VL and JL coding sequences and mouse immunoglobulin variable gene locus non-coding regulatory and/or scaffold sequences, wherein the engineered partly bovine immunoglobulin locus of the transgenic mouse is functional and expresses immunoglobulin chains comprised of bovine variable domains and mouse constant domains.